We are IntechOpen,
the world's leading publisher of
Open Access books
Built by scientists, for scientists

## 4,800
Open access books available

## 122,000
International authors and editors

## 135M
Downloads

Our authors are among the

## 154
Countries delivered to

## TOP 1%
most cited scientists

## 12.2%
Contributors from top 500 universities

**WEB OF SCIENCE**™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com

# Epigenetic Mechanisms of the Vascular Endothelium

Alexandra A. Majerski, Anthony C. Quinton and
Philip A. Marsden

Additional information is available at the end of the chapter

## 1. Introduction

In the same way that Watson and Crick's breakthrough in identifying the molecular structure of the DNA double helix revolutionized the last sixty years of molecular biology, the field of epigenetics is set to do the same for the next sixty (or more) years! An alphabet of four letters, and strict guidelines dictating their arrangement, comprise the genome of all known living organisms. This same system has allowed us to unravel many of the secrets to human health and to comprehend a great number of once-elusive conditions and diseases. Nevertheless, a vast number of puzzles remain to be solved, and the genetic code is but one tool used to make sense of them.

Our understanding of our genetics has grown enormously over the last several decades and the iconic image of the DNA double helix has become a cornerstone for the field. Most certainly, the information contained within this static DNA code is but a starting point. Yet, a number of seemingly straightforward questions cannot be answered without going beyond the highly conserved script. Undoubtedly, many ask: Why and how is an endothelial cell different from a brain cell when the static DNA genome is identical? To answer this and many other complex and fascinating phenomena, we must, instead, go over or above (epi-) genetics because the DNA blueprint is identical in each of the abovementioned somatic cells. A term coined in the 1940s by Conrad Waddington, epigenetics refers to chromatin-based mechanisms important in the regulation of gene expression that do not involve changes to the DNA sequence per se. Epigenetic principles, in eukaryotic organisms, are linked by an important common thread: DNA does not exist in a "naked" state. Figure 1 provides a visual representation of the added layer of chemical species, as well as proteins which themselves can be modified – all of which contribute to a layer of chemical complexity and significant implications that epigenetics strives to classify and understand.

Division and differentiation are fundamental processes for sending cells of common origin to different destinations. Logically, the timing and regulation of these processes must be dependent on more than an identical code contained in all body cells. Thus, the epigenome comprises the ever-expanding repertoire of chemical alterations that regulate the expression of genes and, hence, dictate the function of cells and the role of proteins. A number of genetic determinants, as well as lineage-specific markings, and environmental responses are used to construct the epigenome [1]. The existence of an epigenetic code is a highly contested topic [2] and one which will be explored throughout this chapter. Indeed, it is not only mistakes in the genetic code, but also deviations in the epigenome that may provide clues to understanding the onset of detrimental conditions and diseases.

## 2. Three mechanisms of epigenetics

### 2.1. Posttranslational histone modifications

Compaction of the entire 6 billion base pair genome, 3 billion in each copy of the haploid genome, into each one of 50 trillion human body cells is a truly breathtaking achievement! In each cell, 2 meters of DNA are condensed by at least 10, 000 fold in order to fit into the roughly 6 μm diameter of the nucleus. In accomplishing this monumental feat, intricate folding and wrapping are the first steps in organizing the DNA. Covalent and non-covalent interactions further alter the three-dimensional arrangement of the chromatin. Chromatin refers to the state of DNA when it is spooled around the fundamental repeat unit: the nucleosome [3]. Each nucleosome consists of an octamer containing four different core histone units: histones H2A, H2B, H3 and H4. Two of each core histone unit are present within one nucleosome such that a tetramer of H3 and H4 joins two dimers of H2A and H2B [3]. At least one fifth of the amino acids in each core protein are lysine or arginine – those with highly basic side chains [4]. Approximately 147 base pairs of DNA wrap around each nucleosome. Linker histones, especially H1, interconnect each nucleosome. Structurally, each of the canonical histone core proteins has a characteristic N-terminal tail of amino acids extending out from the core, which is highly susceptible to modifications [3].

Contrary to what biologists believed for many years, kinetic experiments have shown that DNA wrapping around a nucleosome is surprisingly dynamic. Open exposure for 10 to 50 milliseconds – the length of time between rapid winding and unwinding – means that DNA is available for binding other proteins [5]. The formation of nucleosomes converts a DNA molecule into thread-like chromatin approximately one-third of its initial length [4].

Since the initial work in histone acetylation and methylation by Allfrey and colleagues [6], many other modifications have been documented, with the most frequently found to be, at steady state, lysine acetylation, mono-, di-, and tri-methylation of lysines, and the phosphorylation of serines [7]. Concomitantly, a particular collection of enzymes is responsible for each of these additions: histone acetyl transferases (HATs) and histone methyl transferases (HMTs). Importantly, each of these modifications are reversible, the opposite reactions catalyzed by a group of histone deacetylases (HDACs) and histone demethylases (HDMTs). Most often, the

**Figure 1.** Three defining epigenetic mechanisms: DNA methylation, posttranslational histone modifications, and RNA-based mechanisms. The four-lettered (**a**denine, **c**ytosine, **g**uanine, **t**hymine) code that constitutes an individual's genetic makeup is identical in all cell types and is highly conserved during mitotic and meiotic divisions, whereas the three epigenetic modifications differ amongst cell types and are only partly conserved during mitosis and meiosis. In the "Nurture vs. Nature" debate, genetics characterizes the latter with strong evolutionary convergence while epigenetics is influenced by the former, such that the dynamic patterns that classify it diverge rapidly through evolution.

binding of DNA gene regulatory proteins, or transcription factors, is a pre-requisite for the recruitment action of any of these enzymes. Such events occur at different times in the developmental history of a cell and groups of nucleosomes may be modified in a multitude of ways based on the status of the cell [4].

The mechanism by which histone posttranslational modifications (PTMs) occur can be broadly categorized into 3 groups: a) altering chromatin structure with small (acetylation, phosphorylation, methylation) or large (ubiquitylation, sumoylation) chemical groups, b) inhibiting binding factors to the chromatin, and c) attracting a particular set of proteins to the newly modified regions. In the following, we will highlight the notable features of the well-studied mechanisms and allude to the implications of them throughout the remainder of this chapter.

First, acetylation is a posttranslational histone mark that is known to be correlated with transcriptional activation. Broadly speaking, chromatin structure is loosened by the acetylation of lysine (denoted by K) residues. This modification allows for DNA binding sites to be made more accessible, at the same time that a new collection of proteins are recruited to this region of modified chromatin [8]. Positive charges at highly basic histone tails are neutralized with lysine acetylation, which reduces the binding of the amino acid to the negatively charged DNA [9]. An actual change of the physical properties of the histone tails, such as neutralization, is an example of a *cis*-effect. In this instance, a segmental expansion of the chromatin allows for easier access to transcriptional regulators. When other proteins are actively recruited to the chromatin and read snippets of it, a *trans*-effect is said to occur. The example HPTM recruiting new proteins was observed with histone tail acetylation. Bromodomain are specialized protein domains, found in HATs such as Gcn5 and CBP/p300. [10, 11].

Histone methylation has proven to be more perplexing than histone acetylation due to the fact that lysine can be mono-, di-, or tri-methylated and arginine can be mono-or di-methylated. Knowing that there are 24 sites of lysine and arginine methylation on the four histone core proteins, means that a tremendous number of methylated/unmethylated states are possible [12-15]. Astonishingly, lysine methylation can result in either the activation or silencing of gene expression. Generally, the methylation of lysines 4, 36, and 79 on histone H3 (H3K4me, H3K36me, H3K79me, respectively) are correlated with transcriptional activation, while the remainder have repressive activity [15]. Two of these marks, namely methylation on lysine 79 of histone H3 and 20 on histone H4, also play a vital role in DNA repair [15]. Arginine methylation is similar, in that the process has been correlated with both negative and positive transcriptional regulation in numerous contexts [16-19].

In contrast to the addition of small chemical species, other larger modifications of histones are described (acetyl, phosphate, and methyl). Ubiquitylation and sumoylation, the addition of ubiquitin (Ub) and small ubiquitin-like modifier (SUMO), respectively, increases the size of the histone by up to two-thirds [20]. Depending on the site of ubiquitylation, this process can result in either transcriptionally active or inactive segments of chromatin [21]. Currently, there are no known ubiquitin chromatin binding proteins, but it is hypothesized that ubiquitin protein is again likely involved in a more diverse array of interactions than are the smaller chemical additions. Although much less well studied, SUMO is thought to recruit deacetylases and/or block lysine substrates that could be acetylated. Both mechanisms are consistent with results that have shown sumoylation to be correlated with transcriptional repression [20].

As a final note on PTMs, chromatin remodelling complexes that rely on the hydrolysis of ATP are known to temporarily alter the structure of nucleosomes by reducing the attraction between DNA and its neighbouring histone. This is commonly referred to as "nucleosome sliding" and the action briefly makes the DNA more susceptible to the effects of other proteins [4]. This sequence of events likely allows for a greater range of interactions of which we are not yet fully aware. It is important to stress that chromatin structure is highly regulated by nucleosome eviction and alternative histone core protein usage. This is a new area of study.

## 2.2. DNA methylation

The second major epigenetic pathway is DNA methylation - the addition of a methyl group (-$CH_3$) to the five position of the nitrogenous base, cytosine (Figure 1). Often referred to as the "fifth base pair," the product of this reaction, 5-methylcytosine (5mC), is the most common mutagenic base in the mammalian genome. Mutation of methyl CpG to uracil pG then TpG results in CpG depletion and TpG enrichment in the mammalian genome. DNA methylation is predominantly observed at CpG sites in the mammalian genome, with the methyl modification at non-CpG dinucleotides unusual, except perhaps in stem cells and mature neurons. Not to be confused with cytosine complementarily binding with guanine *across* the DNA double helix, CpG sites refer to locations where cytosine and guanine are separated by a phosphodiester bond, adjacent to one another. The vast majority, approximately 70-80%, of all CpG sites in the mammalian genome are, indeed, methylated [22]. Distribution of methylation

across the genome shows enrichment at centromeric heterochromatin, repetitive element (transposon), and non-coding regions [23].

Unlike the great variability of histone modifications, DNA methylation is well known to be a mark of transcriptional repression [24]. Having been the first epigenetic mechanism identified, DNA methylation has been studied for the longest time and its consequences are well entrenched in a variety of essential biochemical processes, abnormal conditions, and diseases. X chromosome inactivation and imprinting are two such phenomena where normal DNA methylation in early development plays a vital role in setting the stage for monoallelic expression from chromosones during cellular maturation [25]. Deregulation of the methylation mechanism can lead to Immunodeficiency Centromeric instability, and Facial abnormalities syndrome (ICF) as well as being a contributing factor to cancer progression [26].

There are two main hypothesized mechanisms by which DNA methylation is proposed to repress gene expression. The first of these is a physical interference with the binding of regular transcription factors. The methyl group itself may physically project into the major groove of the DNA double helix, whereby it interferes with the sequence-specific recruitment of DNA proteins [27]. In support of this, a number of transcription factors have been found to recognize GC rich regions of the genome – the very same regions that are most susceptible to CpG methylation. Subsequently, these factors are unable to bind when methylcytosine takes the place of cytosine. The second proposed mechanism is in opposition to the first, as proteins are not repelled by the presence of 5mC, but are instead attracted to it. After the purification and cloning of an individual methyl-CpG binding protein, MeCP2 [28], four more similar proteins were identified and are now referred to as methyl-CpG binding domain proteins (MBDs). The attraction of these MBDs has been shown to block the binding of activating transcription factors and to actually recruit to the chromatin, histone-modifying enzymes, chromatin remodelers, and RNA molecules [29-31]. Several such conglomerates have been proposed to co-operatively silence gene expression [32].

### 2.2.1. DNA methyltransferases

The reaction that yields 5mC as its product is catalyzed by a family of three DNA methyl-transferases (DNMTs): DNMT1, DNMT3A and DNMT3B [33]. DNMT1, the first of three family members, is a maintenance methyltransferase as it is responsible for transmitting methylation patterns from one cellular generation to the next. Replication of DNA demands that the two strands first be unwound, and it is during this time that DNMT1 is recruited to the replication fork. Binding of proliferating cell nuclear antigen (PCNA) to both strands and UHRF1 (ubiquitin-like with PHD and RING finger domains 1) protein via its characteristic SET-and RING-associated (SRA) domain, are pre-requisites for the recruitment of DNMT1 [34-36]. This enzyme exhibits methylation preference for hemi-methylated DNA, that is, double stranded DNA where only one strand exhibits methylation [37, 38]. Following replication, the parent strand displays the necessary methylation patterns and is subsequently used as a template for the DNMT1-mediated methyl addition to the nascent, naked strand of DNA. Such sites are accurately methylated due to the palindromic nature of the CpG sequences and the fact that methylation patterns between the two strands are symmetrical. Two other DNMTs include

DNMT3A and DNMT3B, both of which have been shown to function as *de novo* methyltransferases, displaying preferential methyl addition to unmethylated DNA [39]. These DNMTs play a crucial role in embryonic development, during which time the methylation patterns to be propagated in somatic cells are established [40].

The catalytic domain of the DNA methyltransferases is conserved amongst all of the DNMTs. Despite this, very little similarity is seen at their N-terminal domain. The regulatory domain of DNMT1 is composed of at least five motifs that are not present on the other enzymes, whereas DNMT3A and 3B exhibit two unique motifs. DNMT1 motifs include: a PCNA-interacting domain, a nuclear localization signal, a replication foci-targeting domain, a DNA-binding CXXC region, and a protein-protein interaction motif called the bromo-adjacent homology domain [26]. Those of DNMT3A and 3B include a motif essential for heterochromatin association, PWWP [41, 42] or "pro-trp-trp-pro," as well as a motif for protein-protein interactions: the ATRX-related cysteine-rich region containing a zinc finger and an atypical PHD domain [26].

### 2.2.2. CpG Islands

The fact that 5mC is the most common mutagenic base of the mammalian genome can be explained by methylcytosine's susceptibility to deamination [43, 44]. Upon deamination, the modified nitrogenous base is replaced by thymine and a T:G mismatch is generated. Rather than the rapid repair mechanism activated by cytosine deamination to uracil, T:G mismatches tend to accumulate and are not readily removed. Consequently, the genome becomes CpG depleted and TpG enriched. As indicated in Table 1, CpG islands (CGIs) are regions of the genome that have been spared this phenomenon; the number of CpG sites observed (O) is equivalent to the number that would be expected (E) based on C or G nucleotide abundance. As a result, the ideal situation would be an O/E of 1.

The definition of a CpG island has undergone a great deal of revision since the earliest studies dealing with these genomic regions [45] and are now rather arbitrarily defined as being > 500 bp [46], but averaging around 1000 bp. The O/E range determines the strength of a CpG island with the strongest having O/E > 0.75, a weak one with an O/E between 0.45 and 0.75, and a poor CGI having an O/E < 0.45. These regions are characterized by their elevated C+G content with the %C+G content > 55% [46]. These segments are especially fascinating due to their unusually low levels of DNA methylation marks. In essence, these regions are very often observed to be unmethylated. Due to the lack of repressive flags, genes that are downstream of CGI containing promoters are often in an active state of expression. It has been speculated that practically all CGIs are transcription start sites (TSS), largely of housekeeping and developmentally important genes [47, 48]. Approximately 70% of all gene promoters are CGIs [49].

The relationship between structure and function is seen most vividly in many of the compositional characteristics of CGIs. For instance, a recent study found that the CGI at the promoters of a particular group of genes was relatively nucleosome-deficient [50]. That is, the underlying DNA was highly accessible to activating transcription factors because less of it was spun around nucleosomes. Evidence from additional studies has shown that this nucleosome

deficiency is a feature of CGI promoters, in general [51-53]. It is not yet known whether this phenomenon is a result of intrinsic chromatin instability or nucleosome exclusion due to the presence of the transcription initiation complex. Interestingly, it was found early in the study of CpG islands that, when found at promoter regions, these segments lack the canonical TATA box that so many eukaryotic promoters possess [54, 55]. Constitutive binding of RNA polymerase II is a frequently documented feature of CGIs. Presence of RNA polymerase II would evidently be associated with transcriptional activation as it is the major player involved in regular transcription.

Several histone chromatin features are also known to typify CpG islands, one of which is the depletion of histone 3 lysine residue 36 dimethylation, H3K36me2 [56]. Even though no conclusion has been reached as to why it is the absence of this dimethylation that characterizes most CpG islands, the modification has been reported, in yeast, to inhibit transcriptional initiation via histone deacetylase attraction. [57-59]. This absence makes way for the transcriptionally permissive state of CGIs. Furthermore, CGIs are marked by activating histone acetylation; both H3 and H4 acetylation are frequently observed [51, 60]. Notably, Cfp1 (CXXC finger protein 1) is a well characterized and fundamental component of the Setd1 H3K4 methyltransferase complex [61] and is drawn towards the overwhelming majority of CGIs in the mouse genome [62]. In the context of CpG islands, this protein directs H3K4 trimethylation, the activity of which has been shown to prevent DNA methylation of the underlying code [63, 64]. Hence, the DNA is maintained in a potentially active transcriptional state.

### 2.2.3. 5-hydroxymethylcytosine: the 6ᵗʰ base pair

The long-standing study of DNA methylation took a significant turn in 2009 with the rediscovery of what is now commonly referred to as the "6th base pair:" 5-hydroxymethylcytosine (5hmC) [65]. This base is the product of an enzymatic reaction that adds a hydroxyl (-OH) group to the methyl of 5-methylcytosine as shown in Figure 2. 5hmC was initially detected in 1972 in mammalian DNA [66], but has since been found primarily, and abundantly, in Purkinje neurons [67], the central nervous system (in the brainstem, spinal cord, and especially the cerebellum [67] and cerebral cortex) [68], and in embryonic stem (ES) cells [65, 69]. The highest tissue levels of 5hmC have been consistently found in the brain [69-71]. The striking abundance of 5hmC in ES cells and PGCs has led scientists to delve into the possibility that 5hmC is linked with the removal of 5mC in such settings, *in vivo*. There is evidence to suggest that, unlike 5mC, 5hmC may be correlated with transcriptional activation, after having been found at euchromatic regions in mice [72, 73]. In essence, while 5mC is known to be a mark of transcriptional repression, 5hmC may be associated with turning genes back on. Since 2009, a large quantity of research has been generated, dedicated to studying the potential role of 5hmC in gene expression regulation. Despite this, we have only just scratched the surface of discovery as the role of 5hmC in the genome continues to remain highly elusive.

A vital question regarding 5hmC is whether it functions as an intermediate in enzymatic reactions or as a stable entity unto itself. In this chapter, considerable space will be dedicated to discussing the possible demethylation pathways in which 5hmC is speculated to be involved. In this and many contexts, demethylation is defined to be the removal of 5mC and

| Distinguished by | Unusually high levels of CpG sites, within a GC rich region, in comparison to the rest of the genome | | |
|---|---|---|---|
| GC percentage | % C + G > 55% | | |
| Length | Arbitrarily defined as > 500 bp | | |
| | Average 1000 bp | | |
| Location | Most often associated with transcription start sites (TSSs) | | |
| | Roughly 70% of mammalian gene promoters contain CGIs | | |
| Classification of CGI | Strong CGI | O/E > 0.75 | |
| | Weak CGI | 0.45 < O/E < 0.75 | |
| | Poor CGI | O/E < 0.45 | |
| Epigenetic Patterns | Generally unmethylated | | |
| | H3K36me2 depletion | | |
| | Nucleosome deficiency | | |
| | Histone acetylation (H3/H4 Ac) | | |
| | H3K4me3 enrichment | | |
| | Cfp1 binding | | |
| | Constitutive binding of RNA polymerase II | | |

CpG islands are regions of the genome that have remained CpG, rather than TpG rich, the latter being the product of CpG deamination that has taken place over evolutionary time. O/E indicates the ratio of observed CpG sites: expected number of CpG sites. Strong CGIs tend to have a high O/E meaning that the number of observed CpG sites is approaching the expected number of CpG sites, making for a maximum O/E of 1. Often unmethylated, these regions of the genome are associated with transcription start sites. A number of epigenetic patterns have been found to characterize CGIs (H3K36me2=dimethylation of lysine 36 on histone H3 and H3K4me3=trimethylation of lysine 4 on histone H3).

**Table 1.** Characteristics of CpG Islands (CGIs)

(eventual) replacement by cytosine. In the majority of these pathways where 5hmC is required, it is often thought to act as an intermediate, rapidly replaced by another chemical species. Levels of 5hmC are substantially lower than 5mC in the genome, at approximately 10% of 5mC and 0.4% of all cytosines [74]. These minute levels are thought to be consistent with the short-lived species hypothesis as elevated levels would indicate a longer duration. If 5hmC generation is merely a pre-requisite for subsequent demethylation pathways regardless of what form they take, then 5hmC would be considered a transient species.

Evidence is also emerging which supports the notion of 5hmC as an entirely new landmark in the epigenetic gene regulatory landscape. In fact, the modified nitrogenous base may even be responsible for attracting a unique panel of chromatin and transcriptional modifiers. Numerous mechanisms have been proposed based on preliminary observations. Methyl-CpG binding domain protein 1 (MBD1) specifically recognizes methylated DNA and attracts histone deacetylases and H3 lysine 9 methyltransferases (also repressive in action) [75-79]. 5hmC has

been shown to greatly inhibit the binding of these MBDs to DNA [80-82]. On the same note, DNMT1 is also well known to recruit H3K9 methyltransferases, but the enzyme is blocked by the very presence of 5hmC, so the likelihood of H3K9 methyltransferase binding is also reduced. Methylation has also been implicated in nucleosome compaction, making DNA less accessible to transcription factors [83]. Conversely, the effect of 5hmC on nucleosome compaction has yet to be determined, but the nuclei of Purkinje neurons have been reported to exhibit marked decondensation [84].



This figure is adapted from Matouk CC, Turgeon PJ, Marsden PA. Epigenetics and stroke risk-beyond the static DNA code. Advances in Genomics and Genetics. 2012;2012:2:67-84.

**Figure 2.** Methyl modification to cytosine and hydroxyl addition to 5-methylcytosine. The addition of a methyl group at the 5-position of cytosine is mediated by the DNA methyltransferase (DNMT) family, where S-adenosylmethionine serves as the methyl donor. Notes: The ten-eleven translocation (TET) family of enzymes is able to oxidize 5-methylcytosine to 5-hydroxymethylcytosine in an oxygen-dependent reaction requiring adenosine triphosphate and 2-oxoglutarate. Cytosine can then be generated from the action of putative demethylases on 5-hydroxymethylcytosine, but has not yet been fully described.

### 2.2.4. Ten eleven-translocation (TET) enzymes

The 2009 seminal paper by Tahiliani *et al.* identified the TET (ten-eleven translocation) enzymes as being those responsible for the generation of 5hmC by the hydroxylation of 5mC [65]. Adding yet another layer of complexity to uncovering the role of 5hmC in the genome, TET enzymes are also responsible for the further oxidation of 5hmC into new products: 5-formylcytosine (5fC) and 5-carboxycytosine (5caC) (70, 85, 86). TET enzymes are present throughout the Metazoa and the three forms, TET1, TET2, and TET3, are thought to have arisen as a result of a triplication event that occurred in jawed vertebrates [87]. All three murine forms have been seen to oxidize 5mC to 5hmC *in vitro* and *in vivo* [88, 89]. Moreover, the presence of 5mC consistently appears to be a pre-requisite for the generation of 5hmC *in vivo* [69, 72], suggesting that TET-mediated oxidation is the only means of formation. All of the TET proteins are $Fe^{+2}$ and 2-oxoglutarate dependent dioxygenases (65, 88, 90). The term, *dioxygenase*, refers to an enzyme that catalyzes the addition of both oxygen atoms from molecular oxygen to another organic substrate. The iron ion is utilized as a co-factor, whereas 2-oxoglutarate is a co-substrate.

The mammalian TET enzymes all exhibit a high degree of homology amongst their C terminal domains. It is the Cys-rich and double stranded-helix DSBH region (CD domain) [87] belonging to the Cupin-like dioxygenase superfamily, that contains the catalytic domain for 2-oxoglutarate and iron (II) activity [65, 88]. Further oxidation of 5hmC into 5fC and 5caC also takes place at this same active site [85]. This CD domain also contains the largest identifiable portion of the enzyme: the spacer region. For the most part, the function of this region is unknown, although some leads for future research do exist. For instance, Upabhyay *et al.* noted remarkable sequence overlap between the spacer region of TET1 and the C-terminal domain of RNA polymerase II of *S. cerevisiae* [91]. Likely of most significance are the conserved residues that are key sites for posttranslational modifications such as histone methylation and phosphorylation [92]. Located on the N terminus (~60 amino acids) of TET1 and TET3 (not TET2) enzymes is the CXXC zinc finger domain [65, 87]. Even though its function has not been conclusively determined, the CXXC domain in TET1 has been shown to bind to unmodified cytosine, as well as 5mC and 5hmC [93, 94]. Speculation has tended towards this domain serving as the functional unit responsible for directing the enzymes to particular genomic regions, almost always CpG sites, so they can execute their oxidative action [92]. A similar CXXC domain on DNMT1, the enzyme on which it was first discovered, possesses comparable DNA binding properties [95], initially having suggested an equivalent role for the domain in TETs.

## 2.3. Long non-coding RNA

Contrary to the central dogma of biology, in which RNA plays a passive role in transmitting genetic information to be translated into proteins, recent advances have shown RNA to play a much more active role in cellular regulation. Long non-coding RNAs (lncRNAs) are the most recent and least well characterized of functional "non-coding" RNAs. The distinction between lncRNAs and miRNAs is arbitrary, but has been defined as greater than 200 nucleotides for an lncRNA [96]. Unlike miRNAs, however, which seem to function through similar pathways, lncRNAs have been shown to play a diverse assortment of regulatory roles, including posttranscriptional repression, RNA splicing, and RNA degradation [97]. Despite this variety, perhaps the most interesting and well-studied mechanism is the ability of many lncRNAs to act as epigenetic modulators, interacting with chromatin remodeling complexes and other epigenetic machinery [98].

*Xist* was one of the first lncRNAs to be discovered [99] and, consequently, is the most well described. The *Xist* gene is found in the X chromosome inactivating center (XIC) where it plays a major role in the inactivation of one of the two X chromosomes in females [100], a process which equalizes X chromosome dosage to that of a male karyotype. *Xist* acts in *cis* to repress the transcription of the chromosome on which it is transcribed [101]. *Xist*'s function as an epigenetic regulator was confirmed with the discovery of an interacting factor, the polycomb repressive complex 2 (PRC2) [102], a complex that mediates the repressive histone trimethylation mark H3K27me3. PRC2 is recruited to the inactive X chromosome (*Xi*) by a short repetitive sequence, Repeat A (*RepA*), conserved on the *Xist* transcript [102]. Tethering of *Xist*

to the chromosome from which it was transcribed allows for allele specific recruitment of the PRC2 complex and subsequent inactivation [101].

Another important lncRNA in X chromosome inactivation is the *Xist* antisense RNA, Tsix. Tsix is expressed on the active chromosome and blocks *Xist* expression, thereby preventing its inactivation [103]. The action of Tsix illustrates another mechanism of epigenetic regulation in which lncRNA can take part: DNA methylation. Recently, evidence has suggested that Tsix mediates DNA methylation at the *Xist* promoter, silencing the *Xist* gene [104]. Tsix may activate DNA methyltransferase 3A (DNMT3A), one of the *de novo* methyltransferases, and guide it to the *Xist* promoter where it is involved in maintaining the silencing of the *Xist* gene after initial repression.

X chromosome inactivation is not the only cellular process in which lncRNA is involved, and there are numerous other examples of lncRNAs as epigenetic regulators. For example, HOTAIR is an lncRNA located in the homeobox C (HOXC) cluster of genes [105]. The *HOX* genes are a family of genes that serve as developmental cues in the embryo [106]. The expression pattern of different *HOX* genes corresponds to specific tissue development and ensures the correct relative positions of body parts. The 39 *HOX* genes are present in 4 gene clusters, HOXA-D, each present on a separate chromosome [107]. HOTAIR is expressed in the HOXC cluster where it acts in *trans* to suppress expression on the HOXD cluster. In this way, HOTAIR is required to maintain the specific expression pattern of *HOX* genes throughout embryonic development. Like the *Xist* RNA, HOTAIR achieves this repression through the recruitment of the PRC2 complex, which then catalyzes the repressive H3K27 trimethylation mark. Indeed, knockdown of HOTAIR has shown loss of H3K27 trimethylation in the HOXD gene cluster, as well as an absence of the PRC2 complex. This suggests that ncRNA may be a global requirement for activation of PRC2 H3K27me3.

## 3. DNA methylation and development

Most methylation patterns are stably inherited, remaining static throughout the lifetime of an organism. Specific cellular processes as well as cell-lineage specificity require activation or elimination of these patterns. Fluctuations in 5mC and 5hmC levels are most vividly seen in the cases of pre-implantation development and primordial germ cell formation (Figure 3). In order to understand the significance of the rapid changes in modified cytosine levels, a number of recent and vital observations must be taken into account.

### a. Pre-implantation embryo

Throughout the duration of development, especially cellular differentiation, somatic-cell lineages acquire specialized DNA methylation and histone modification patterns. Even in the earliest stages, both sperm and oocyte are known to contain appreciable levels of DNA methylation. Many of the methylated regions are shared between oocyte and sperm, such as intracisternal A particles (IAPs) [108], although there are differentially methylated regions (DMRs) which is oocyte-or sperm-specific. Active and repressive histone modifications are

present in the oocyte at this time [109], and it is maternally inherited proteins that will direct the events of early cleavage divisions. On the other hand, sperm arrive with temporary histone substitutes, protamines, which play a similarly functional role in packaging [110].

Upon fertilization, the sperm genome is the earliest to undergo major modifications, the first of which is protamine removal and substitution with histones [111]. Prior to the fusion of the maternal and paternal pronuclei, a vast genome-wide demethylation event occurs in the paternal pronucleus [112-115], whereby its methylation patterns are erased almost in their entirety. This event can occur in as few as six hours following fertilization [112, 113, 116]. This demethylation has been assessed repeatedly via immunostaining with antibodies specific for 5mC [112, 113, 116] as well as bisulfite sequencing which has clearly shown that one of two genomes becomes demethylated. A recently discovered and intriguing fact is that this genome-wide demethylation is actually a mass oxidation event [117-119]. 5mC specific antibodies do not recognize 5hmC or any other oxidized cytosine, yet it has been repeatedly and conclusively demonstrated that the male pronucleus does exhibit a marked increase in 5hmC levels at this time [117-119]. Complimentary antibody staining has taken place in order to deduce this. Regions unaffected by this event include paternal DMRs in imprinted genes [120, 121] and IAPs [108]. It is now well known that it is the maternal TET3 enzyme that executes the oxidative action on the paternal pronucleus [119]. In contrast to the other TET enzymes, TET3 knock-down has been demonstrated to result in the near deficit of 5hmC.

The presence of histone modifications unique to the maternal pronucleus is linked to its spared erasure at this time of otherwise mass oxidation. Developmental pluripotency-associated 3 protein (DPPA3, also known as stella), has been identified as the key protector of the maternal pronucleus as well as that of a few paternally imprinted genes [122]. As a matter of fact, the protection offered by this protein is almost indisputable, as experiments have shown that an absence of DPPA3 results in the hydroxymethylation of both paternal and maternal genomes [117, 122]. This protein was originally identified as a result of the upregulation of its encoding gene during initial PGC development [123]. Dimethylation of H3 histone at lysine 9, a mark that is restricted to these sites [122], has been reported to be responsible for the attraction of DPPA3 to these regions.

As indicated in Figure 3, the 2-16 cell stage exhibits a substantial decrease in both maternally dominant 5mC and paternally specific 5hmC levels. It is a well known fact that the maternal genome also loses all methylation marks during early embryogenesis. This, however, has not been attributed to a mass oxidation event, hence, no generation of 5hmC takes place at this time. The cytoplasmic localization of DNMT1o, a splice variant of DNMT1, is attributed to the passive replication-dependent dilution of all oxidized cytosines, [112, 116, 124] accounting also for maternal genome methylation erasure. That is, with each division, 50% of the genomic methylation and hydroxymethylation patterns are lost due to the absence of maintenance methylation [125], until virtually no modified cytosines remain by the sixteen cell stage [112, 116].

Another generally accepted fact is that a wave of *de novo* methylation takes place at approximately the time when the blastula implants into the uterus [116, 120]. This activity occurs very rapidly and 5mC levels plateau once all of the necessary methylation patterns have been

instilled (Figure 3). That is, no more demethylation is known to take place because patterns placed onto the genome at this stage are the same as those that will be found in somatic cells of later development and maturation. This *de novo* methylation is now known to be catalyzed by the *de novo* methyltransferases 3A and 3B [116]. In fact, inactivation of both DNMT3A and 3B has been shown to result in early embryonic lethality while mutations in the encoding genes have also resulted in postnatal or embryonic lethality [126, 127]. Establishing the patterns of the genome at this stage allows for the predictable mitotic transmission of methylation marks throughout the lifetime of an organism [40].

As opposed to the undoubtedly critical role of TET3 following fertilization in mice, TET1 and TET2 are thought to have modulatory, yet not essential roles in development, ES cell endurance, and pluripotency [84]. At the blastula stage, the function of TET1 and TET2 proteins in the inner cell mass is likely to repress lineage-specific genes, counteracting the effect of methylation, so as to permit activation of certain genes later in development [128, 129]. Consequently, they are thought to be fine tuning methylation patterns at this point [84].

Consistent experimental results indicate that there is, however, much still to be confirmed about the relative role of TET proteins in development. As a point of discrepancy, TET1 deficient mouse ES cells have been seen to maintain their self-renewal capabilities *in vitro* and develop ordinarily *in vivo* [130]. Furthermore, numerous groups have demonstrated that the knockout of both TET1 and TET2 results in the normal development and healthy adulthood of fertile mice [130-134]. It is hypothesized that such discrepancies may be a result of the alternate TET proteins compensating for the depletion of one another [92]. Although the biological roles of TET1 and TET2 in zygotic development are still highly disputable, that of TET3 appears to be more comprehensive. One study, in particular, highlighted the importance of this particular enzyme in embryogenesis by introducing a homozygous mutation in the TET3 encoding gene, subsequently observing neonatal lethality [119]. The same study came to the conclusion that failure to demethylate the male pronucleus is a direct result of TET3 depletion.

Evidently, epigenetic modifications play an unquestionably enormous role in early development. Despite remaining relatively constant in the mitotic transmission of later development, methylation patterns undergo rapid, yet precisely timed fluctuations in zygotic development. 5hmC abundance points to a vital role of the TET enzymes, as no other pathway has been conclusively verified for the generation of hydroxymethylcytosine from methylcytosine. In light of the recent re-discovery of 5hmC and already substantial amount of scientific inquiry that has gone into deciphering its role in development, we can hope for a great deal more to come in the near future!

### b. Primordial Germ Cells

Primordial germ cells (PGCs) are the cells that ultimately give rise to the germ line, the oocyte and sperm. Similar to what has been observed in zygotic development, mouse PGCs, derived from epiblast cells, are known to experience a correspondingly fast decline in 5mC levels [135] between embryonic day (E) 9.5 and 13.5 [124, 136, 137]. Very recently, Hackett *et al.* decisively demonstrated that the demethylation that takes place in PGCs is conceptually equivalent to

**Figure 3.** Dynamic nature of 5mC, 5hmC, and TET enzyme levels in the pre-implantation embryo and primordial germ cell development. Intensity of purple shading indicates the relative level of modified cytosine at that stage in development. Green shading indicates high levels of TET3 activity, while blue shading shows elevated levels of TET1 and TET2 at these stages in development. Sperm and oocyte begin with high levels of 5mC. Paternal methylation patterns are erased just after fertilization and a mass oxidation event takes place with increasing levels of 5hmC by the zygotic stage. 5mC and 5hmC (from the paternal genome) levels diminish by means of a passive-replication dependent manner whereby both the maternal and paternal genomes are practically devoid of either modified cytosine by the 16 cell stage. Upon implantation in the uterus, mass *denovo* methylation takes place whereby somatic cell methylation patterns are established. Primordial germ cells are also subject to demethylation between E9.5 and E13.5, accompanied by increasing 5hmC levels until approximately E 11. Paternal re-methylation takes place beginning at about E15 and, in females, after birth.

the mass oxidation event that has been observed during embryonic development. In this case, TET1 and TET2 are responsible for the generation of 5hmC [124, 138].

Thus far, the acquisition of 5hmC appears to take place between E9.5 and E11.5 [124], but seems to be lost at a rate that is typical of replication-dependent pattern dilution [124]. Such circumstances closely parallel those seen in zygotic development. In the same way that the DNMT1o splice variant has been seen to be excluded from the nucleus in zygotic development, UHRF1 consistently appears to be down-regulated in PGC formation [84]. Such a situation prevents DNMT1 from performing its prescribed action. Evidence indicates that TET-mediated oxidation in PGCs is likely made possible by passive, rather than active demethylation [124]. This observation is further substantiated by the absence of both 5fC and 5caC following PGC demethylation, as shown in immunocytochemistry studies [124], whereas their presence in zygotic development indicates an increased likelihood for an active demethylation mechanism at work.

By definition, methylation patterns at CpG islands will never be erased during normal development. Yet, CpG island methylation in the DMR of imprinted genes must undergo

erasure so as to ensure that gender-specific methylation associated with imprinting can be put into place during the remainder of germ cell development [123]. Demethylation at this time has also been proposed to be responsible for reinstating the pluripotent state in PGCs. Clearly, those regions whose expression had been repressed are now turned on, allowing for the germ cell lineage acquisition of pluripotent characteristics, perhaps a pre-requisite to achievement of totipotency. Similar to the spared erasure of paternally imprinted genes in zygotic development, certain transposons such as IAPs remain moderately methylated at this time [34].

In contrast to zygotic development, the demethylation of imprinted regions is absolutely critical because germ cells possess imprints that are uniquely exclusive to the gender of the organism. As indicated in the bottom half of Figure 3, an analogous round of *de novo* methylation also takes place later in oogenesis and spermatogenesis. Re-methylation along with the re-installation of imprints starts at approximately E15 in males and, in females, after birth [139].

### 3.1. DNA demethylation pathways

As illustrated above, it is a well ingrained fact that epigenetic reprogramming does take place in zygotic development and PGC formation. More recently, TET protein activity has been observed in relation to the timing of particular developmental events. Consequently, levels of 5hmC have been monitored and correlated with the activity of TET proteins at each stage of interest. Truly novel is the fact that this reprogramming involves a mass oxidation event, that is, the generation of 5hmC. The function of 5hmC in these stages is a highly debated and controversial area of research. We have already addressed the first disputed issue regarding the stability of this oxidized base, but we will now draw our attention to the second debate: What are the possible demethylation pathways by which reprogramming takes place? We will define demethylation as the eventual replacement of 5mC with unmodified cytosine. Possible mechanisms for this can be broadly grouped into passive and active pathways. In analyzing the possibilities, it is important to note that absolutely no consensus exists as to which mechanism predominates and that there is experimental evidence to both confirm and rebuke nearly all pathways.

### 3.1.1. Passive demethylation

Passive demethylation is fairly well established as one of perhaps several operating processes. As mentioned above, the maintenance DNMT places methylation patterns on a progeny strand using the parental strand as a template, similar to the synthesis of a new strand of DNA whereby DNA polymerase utilizes the parent strand as a template for construction of a complementarily base-paired DNA strand. Like the DNA double helix, the maintenance of methylation patterns also occurs through a semi-conservative pathway. This particular setup yields a hemi-methylated (partly methylated) pattern on the DNA. UHRF1 binding and PCNA recruitment are the first steps in the faithful copying of methylation patterns from one strand to another, thereby ensuring the transmission of methylation patterns through mitotic division. From the perspective of demethylation pathways, if this faithful re-installation of methylation patterns is disturbed, every generation will subsequently exhibit 50% less methylation. Eventually, such patterns will undergo what is called passive replication-dependent dilution.

As mentioned, this appears to be the way in which the methylation patterns of the zygotic maternal genome are erased. Thus, the plausibility of this mechanism is not debated. Paternal genome erasure prior to replication is significant evidence that defies the notion of passive demethylation as the *only* demethylation pathway.

As far as active or replication-independent pathways go, the central tenets of a variety of these pathways will be discussed in the following. A common thread that runs beneath a number of these is the coupling of TET protein activity with a well known DNA repair pathway, base excision repair (BER), whereby a nitrogenous base is excised by a glycosylase enzyme and replaced with a new one. Some sort of replacement mechanism is practically inevitable given that an unmodified cytosine must take the place of a previous base in order to complete demethylation.

### 3.1.2. Pathways in which 5fC and 5caC are involved

The first of these proposed pathways involves the other two oxidized bases, 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC) that can be generated by further oxidation of 5hmC by TET enzymes [70, 85, 86]. Their presence at very low quantities in the genome (5fC: 0.03% of 5mC in mouse ES cells; 5caC: 0.01% of 5mC in mouse ES cells) [70, 85, 86], has been attributed to the preference of TET enzymes towards 5mC, not 5hmC, as a substrate, as well as an exceedingly fast removal of the oxidized bases [85, 140]. Thymine DNA glycosylases (TDGs) are capable of excising both bases once they are produced. Kinetic studies by Maiti & Drohat clearly demonstrated that TDG excises 5fC and 5caC, but not 5hmC [141]. Neither when left for a longer time nor performed at a lower temperature (for enzyme stability maintenance) was there any significant 5hmC excision [141]. Excision of the oxidized bases opens the door for base excision repair (BER) action that completes the guanine base on the opposite strand with a brand new cytosine, hence, completing the demethylation pathway. Several labs have confirmed that the proposed is a highly plausible mechanism [85, 141, 142].

Interestingly, a number of studies have shown that TDG exhibits strong specificity in its action: it excises bases which are complementarily base paired with G and/or those which are also followed by guanine [143-146]. Such an observation is entirely consistent with the proposed role of TDG and CpG sites [147] whereby the cytosine has undergone a further modification, yet still fulfills the remainder of the criteria. More research must be undertaken to confirm whether TDG action on modified cytosines, followed by BER, is a plausible demethylation mechanism *in vivo*. Whether such a pathway is of sufficient speed to play a role in demethylation is one concern which must be addressed. Another comes about when we consider the exceedingly minute quantities of both of the bases in the genome: How prevalent can this pathway realistically be? Is it enough to account for mass demethylation in both zygotic and PGC development?

There is limited evidence that supports a decarboxylation pathway of 5caC, mediated by proteins present in lysates of ES cells [148]. Although the factors that catalyze this reaction have yet to be concisely identified, Schiesser *et al.* utilized isotope tracing to detect the direct conversion of 5caC to cytosine without interference from BER [148]. The existence of a

deformylation pathway involved in the direct conversion of 5fC to cytosine has also been postulated.

### 3.1.3. Direct removal of 5-methylcytosine

What about a simple removal of the 5mC base followed by TDG action? Scientists have noted that, due to the strength of the carbon-carbon bond needed to be broken, an enzyme with unwieldy catalytic power would be needed to achieve such a feat [140]. Methyl-CpG binding domain protein 2 (MBD2) was first and foremost reported to catalyze just such a reaction. By its very nature, MBD2 is known to *bind* to methylated cytosine, so it was often questioned how it could be responsible for mediating such an active reaction if it first must attach itself [28, 75]. Numerous other downfalls of this theory emerged and no lab was apparently able to replicate the results, so the theory of MBD2-mediated direct removal of the methyl group of 5mC fell out of favour. Hence, the inevitability of some sort of TDG/BER activity is further substantiated [149].

A model plant used in genetics and epigenetics studies, *Arabidopsis thaliana*, is the only source that has thus far provided evidence for such a direct removal of 5mC (reviewed in [150]). The existence of ROS1, DME, DML2, and DML7-a family of four 5mC DNA glycosylases has been acknowledged in this plant [150]. Their preference for acting on 5mC in double stranded DNA, has led researchers to claim that these enzymes are indeed necessary for active demethylation of particular genes. The function of these glycosylases is similar to that of BER, in that a nick created leaves an abasic site which is rapidly repaired. Yet, the enzymes and mechanisms in mammals appear to be quite distinct from those that have been identified in the plant [151].

### 3.1.4. AID/APOBEC activity

The second well investigated, yet still highly debated active replication-independent demethylation pathway is one which also utilizes a DNA repair pathway. AID (activation-induced cytidine deaminase) and APOBEC (apolipoprotein B mRNA editing enzymes, catalytic polypeptide) family members are primarily known for their ability to deaminate cytosine to uracil [152]. *In vitro* studies have demonstrated the further ability of AID/APOBEC to deaminate 5mC in DNA, to thymine, resulting in a T:G mismatch [149]. The excision conducted by a TDG glycosylase would subsequently result in an abasic site (apurinic and apyrimidinic [AP] site) which would then be subject to repair by BER. The final product of such a chain reaction would be the regeneration of cytosine in place of the modified base [149].

There are a number of variations and caveats of this and related processes. For instance, AID and APOBEC have frequently been seen to function in a single-stranded DNA environment [149]. Deamination in single-stranded DNA has been experimentally observed *in vitro* and in an *E. coli* assay [149]. Despite this, AID and APOBEC are both present at appreciable levels in oocytes as well as PGCs, so their potential role in developmental demethylation has not been dismissed [149].

An alternate pathway through which AID/APOBEC are thought to function involves the deamination of 5hmC to 5-hydroxymethyluracil (5hmU) and its subsequent removal by a TDG

glycosylase or BER pathway [153]. This process would result in the eventual replacement by cytosine. The over-expression of TET1 and AID have been observed to lead to a global accumulation of 5hmU [153]. Two potential pathways may compete with one another because both TDG as well as selective monofunctional uracil-DNA glycosylase 1 (SMUG1) have strong affinity towards the mismatch that would be generated upon deamination: G:hmU [153, 154]. Hence, one of these mechanisms is thought to play a vital role in mediating the downstream commencement of BER following 5mC hydroxylation. Such observations substantiate what many studies propose: that TDG plays an absolutely essential role in active demethylation, regardless of what mechanism succeeds it.

Perhaps what could be considered the downfall of the AID/APOBEC pathway was elucidated in a series of experiments and simulations conducted by Nabel *et al.* [152]. Insisting that the role of this deamination-based mechanism is limited, the researchers examined the plausibility of this pathway by investigating the biochemistry of natural and non-natural modified cytosines. The series of substrates represented a 150 fold difference in reactivity, with the size of the substituent being an integral determinant of susceptibility to deamination. At one end of the scale was unmodified cytosine, the behavior of which as a deaminase substrate was unequivocally superior to all other larger natural and unnatural substrates. The bulky 5hmC not only sterically hindered the activity of AID/APOBEC, but its poor hydrophobic character was also implicated in substantially decreasing its reactivity, in comparison to all other bases. The researchers consolidated their results and firmly stated that AID/APOBEC family members preferentially deaminate unmodified cytosine, yet strongly discriminate against any and all 5-substituted cytosine substrates [152]. Clearly, this result contradicts the notion of 5hmC deamination to 5hmU, and more so favours the other possibility of 5mC deamination to thymine. The hope is that future research will work towards eliminating such discrepancies amongst multiple lines of work as we gain a better understanding of the plausibility of these pathways.

### 3.1.5. DNMT dehydroxymethylation

In addition to AID and APOBEC, the activity of DNMTs themselves has recently been proposed as a possible 5mC demethylation mechanism. In 2012, Chen *et al.* demonstrated that DNMT enzymes can remove the hydroxymethyl group of 5hmC *in vitro* [155]. Hence, 5hmC is directly converted to cytosine [156]. Although it is still unknown whether such a reaction takes place in cells [84], it has been established that reducing conditions favour the generally accepted methyltransferase activity of DNMT3A and 3B while oxidizing conditions are ideal for dehydroxymethylation activity [155]. Participation in both methylation and demethylation results in rapid cycling between the removal and replacement of methylation patterns – a phenomenon that has been reported in two papers to date [157, 158]. In spite of our analysis of a limited number of experiments, both papers refer to the interplay of TDG and BER in this transcriptional cycling. Particular repair proteins were, in fact, recruited to site-specific locations, likely assisting in the reconstruction of the site [140]. Physiological implications must also be taken into account. S-adenosylmethionine (SAM) is required, not only at low levels for the DNMT3A/B mediated reaction, but also at specific levels for other biochemical reactions

[140]. Scientists continue to ponder the other biological effects which would result from rapid SAM level fluctuations.

Quite clearly, numerous potential active demethylation pathways do exist and the validity of one over the other is constantly being reassessed. Further oxidation to 5fC or 5caC, direct removal of the methyl group, AID/APOBEC, TDG, and BER pathways have all been proposed and are now under scientific scrutiny. Numerous sources highlight the possibility of more than one of these pathways operating simultaneously with one or more of the others.

## 4. Case study I: vitamin C

### 4.1. Scurvy

Lethargy, extreme muscle and joint pain, gum disease, loosening of teeth, and emotional instability. Often mistaken for syphilis, leprosy, or dysentery, such were the symptoms that characterized "the plague of the sea" [159].Now a rare disease, scurvy took the lives of two-thirds of Vasco de Gama's men, eighty per cent of Magellan's mates, and terrorized many of those who took to the sea during the Age of Exploration. Little did the famed 15th century explorers know that they were losing members of their crew to a vitamin deficiency. Sailors who boarded ships destined for long journeys relied mainly on cured and salted meats as well as dried grains, and suffered greatly for their deprivation of perishable fruits and vegetables. It was not until its identification and isolation in the 1930s that the association between vitamin C (ascorbate) and its role in scurvy was made. In fact, ascorbic acid, from which the L-enantiomer, ascorbate, is derived, actually means "anti-scurvy" [160].

Unlike many animals, primates, humans, guinea pigs, and a few varieties of fish, cannot synthesize vitamin C *de novo* in the liver [161]. In humans, for instance, the final step of vitamin C biosynthesis cannot be performed: the conversion of L-gulono-gamma-lactone into ascorbic acid. The gene that encodes gulonolactone, the enzyme which catalyzes this reaction, is present in the human genome, but is inactive as a result of mutation accumulation that turned it into a pseudogene [162]. Vitamin C is known to be a critical component of health, while lack of it is truly a detriment to the body because of its dual function in a number of enzymatic reactions as well as its role as an antioxidant.

### 4.2. Collagen biosynthesis

Without a doubt, vitamin C presence is absolutely vital in the regular synthesis of collagen. Being the most abundant protein in mammals and composed mainly of connective tissue [163], the triple helical construction of collagen requires the successful completion of a number of biochemical events. One of these is the essential enzymatic hydroxylation of proline (Pro) residues into hydroxyproline (Hyp) by prolyl-4-hydroxylase (P4H) [164]. A member of a dioxygenase superfamily, P4H decarboxylates the co-substrate, $\alpha$-ketoglutarate, and utilizes $Fe^{2+}$ as a co-factor, yielding hydroxyproline and an oxidized $Fe^{3+}$ [165]. For full catalytic activity, ascorbate is required as another co-factor in the reaction [166, 167]. In the absence of ascorbate,

this reaction can perform at a maximal rate, but only to a certain extent [164]. A buildup of $Fe^{3+}$ requires the activity of ascorbate as a potent reducing agent to regenerate the reduced form of iron: $Fe^{2+}$ [168, 169]. In this way, the catalytic potential of P4H is maintained at an efficient level.

Ascorbate deficiency, the situation which arose when sailors went to sea for several months at a time, leads to the incomplete hydroxylation of proline residues in collagen, which results in its improper folding [170]. Non-functional collagen in blood vessels and bones has been attributed to the severe bone and blood vessel related symptoms that came to characterize scurvy. As a point of interest, the symptoms that extended beyond the changes in bones and blood vessels, have also been linked to vitamin C deficiency. Prolyl hydroxylases are only one of a number of enzymes whose mechanism of action relies on this vitamin. The synthesis of norepinephrine from dopamine, for instance, is catalyzed by dopamine beta hydroxylase, another enzyme which utilizes vitamin C as a co-factor [171]. Required for the generation of metabolic energy via mitochondrial breakdown of fatty acids, carnitine synthesis [172], also necessitates the utilization of ascorbate. Thus, the neurological dysfunctioning of the sailors and their symptoms of lassitude can both be attributed to a lack of this indispensable vitamin.



**Figure 4.** Structure of ascorbate. The vital nature of vitamin C (ascorbate) is exemplified by its dual function in the human body, acting as both a cofactor as well as an antioxidant. Collagen biosynthesis necessitates the hydroxylation of proline residues by prolyl-4-hydroxylase – one of a number of biochemical reactions that require the presence of vitamin C. Belonging to the same family as P4H, TET proteins were proposed as possible enzymes whose catalytic action might also have been augmented by the presence of vitamin C. Recent studies have found that ascorbate is responsible for widespread, yet specific demethylation, by way of inducing the generation of 5hmC by TET enzymes

Thus far, we have explored an interesting historical event that revealed the enormous impact of vitamin C on human health. The indisputably important role of vitamin C is further highlighted by its role in collagen biosynthesis. What's more intriguing is the fact that prolyl hydroxylases belong to the same family as the TET enzymes and share numerous structural features. The possibility of vitamin C interacting with the TET proteins and potentially contributing to the epigenetic landscape of modifications has become an area of scientific interest.

A recent report from Minor *et al*. conclusively stated that ascorbate induces the generation of 5hmC by TET enzymes, likely acting as a co-factor in the reaction [173]. Utilizing mouse embryonic fibroblasts (MEFs), the addition of ascorbate in a time-and dose-dependent manner

was unmistakably seen to correlate with increased 5hmC levels. A novel role for vitamin C in epigenetic modifications has been brought to the forefront. In cells with knocked down TET expression, ascorbate still enhanced the generation of 5hmC by at least 3 fold above basal levels [173]. Rather than protein synthesis, it was shown that the mere accumulation of ascorbate inside the cells was all that was necessary in order to observe increased 5hmC levels. The researchers noted that a detailed mechanism for ascorbate's interaction with the TET enzymes has yet to be elucidated, but the similarity between TET and P4H catalytic action, points towards ascorbate performing a comparable role in TETs as it does for P4H [173].

Due to its enhancement of cell proliferation, vitamin C is a commonly used medium supplement in ES cell culture. A *Stem Cells* report from Chung *et al.* showed that vitamin C, at the concentration used in commercial media (50 μg/mL), promotes widespread DNA demethylation of human ES cells, yet, with remarkable specificity for the location of demethylation [174]. This study showed that the ascorbate-mediated hypomethylation of CpG island shores was highly correlated with gene expression at these sites. A precise set of 1,847 genes experienced altered gene expression as a result of ascorbate addition. From this, researchers speculated that DNA topology may have been changed such that histone demethylase and acetylase activity subsequently altered the accessibility of DNA to other factors [174].

Clearly, numerous connections are being made between vitamin C and the epigenetic landscape. Not only does the vitamin act as a co-factor in enzymatic reactions, but its biochemistry allows it to participate in an even wider array of interactions (Figure 4). As its demethylation potential is remarkably specific in locale, it was first speculated that this vitamin must be interacting with other enzymes to execute its action. Indeed, this interaction has been confirmed in the way that TET enzymes are thought to modulate the actual demethylation with ascorbate acting as a co-factor. Although the exact antioxidant behavior of vitamin C is not thoroughly illuminated here, the potential role of the general class of antioxidants is revealed in the context of the pathogenesis of atherosclerosis. Hence, vitamin C is intricately linked with another underlying theme of this chapter: cardiovascular disease.

### 4.3. Epigenetic mechanisms and the vascular endothelium

Endothelial cells, those that line the lumen of all blood vessels in mammals, mark the interface between blood flow and the entrance of substances into tissues and organs. The endothelium, itself, is composed of a thin layer of endothelial cells and an even thinner layer of basal lamina beneath the cells. Vascular smooth muscle cells neighbour the endothelial cells, but, as will be discussed later, exhibit remarkably distinct gene expression. Vasorelaxation was argued, by Furchgott and Zawadzki, to rely on an intact endothelial lining, from which an endothelium-derived relaxing factor (EDRF) would be released [175]. Soon after, the EDRF was recognized to be nitric oxide (NO) [176, 177]. Nitric oxide is now considered to be an incredibly vital component for maintaining vasculature tone due to its antiatherogenic and antithrombotic properties [177]. Nitric oxide generation is highly implicated in vasodilation, as well as its inhibition of platelet aggregation, leukocyte adhesion, and vascular smooth muscle cell proliferation [178-180].

A number of biochemical pathways in aerobic cells produce oxygen-derived free radicals as by-products. Free radicals are molecules with a single unpaired electron, exhibiting great chemical instability and high reactivity. Donating or accepting an electron normally results in the generation of another free radical. Normal cellular respiration produces $O_2^-$, the superoxide anion, while the hydroxyl radical $OH^.$ is the by-product of the reaction intended to eliminate $O_2^-$. Humans have evolved a number of strategies to combat the production of these reactive oxygen species (ROS). For this purpose, humans are able to utilize diet-derived or *de novo* antioxidants in an effort to convert the damaging species into less toxic substances. Despite this effort, when the levels of reactive oxygen species are appreciably greater than antioxidant levels, a condition known as oxidative stress results. Free radicals, which are further generated from oxidative stress, induce tissue damage and are responsible for detrimental modification of lipids and proteins in the vasculature.

The damaging impacts of oxidative stress are seen nowhere as vividly as they are in the endothelium. Endothelial function is impaired by the conditions and NO production is diminished. The effects are disastrous: reduced vasodilation, enhanced platelet activation, and increased vascular smooth muscle migration and proliferation [181]. In the way that each of these outcomes lead to dysfunctioning of the endothelium, all have severe consequences for the pathogenesis of atherosclerosis. A condition primarily of the intima and a pre-cursor for a number of severe organismal dysfunctions, atherosclerosis can affect arteries as large as the aorta or as small as the tertiary branches of coronary arteries [182].

## 4.4. Pathogenesis of atherosclerosis

The lipid deposition associated with atherosclerosis is derived from an excess of low-density lipoprotein (LDL), the so-called "bad cholesterol," in the plasma. Endothelial damage, such that would occur during oxidative stress conditions, allows for the leakage of LDL into the sub-endothelial space via LDL receptors in endothelial cells [183, 184]. There, the free radical and other oxidized agents attack incoming LDL molecules and generate oxidized LDL (ox-LDL) [184]. Endothelial cells and smooth muscle cells have the capacity to oxidize LDL utilizing free radicals, the presence of which initiated the oxidative stress conditions [185-187]. Expression of adhesive cell surface glycoproteins such as VCAM-1 and ICAM-1 is induced as a result of mildly oxidized LDL [188-190]. Moreover, a variety of molecules within the intravascular space are responsible for attracting and modifying monocytes. An environment such as this, is now rich in modified lipoproteins, chemoattractants, and growth factors, all facilitating the differentiation of incoming monocytes into macrophages. These macrophages are quite powerful in that they are capable of a more relentless oxidation of LDL, acting as phagocytes and promoting smooth muscle cell migration and proliferation [188-191]. These lipid filled macrophages accumulate rapidly and begin to form the foam cells that characterize an atherosclerotic lesion on its way to becoming a clinically significant and potentially severe condition. Because LDL leakage is un-regulated, greater accumulation will lead to the bursting of the cell and an explosion of free radicals and ox-LDL – an event which upholds the cycling of cytoxicity, worsening the damage to the endothelium.

Clearly, the oxidation of LDL exhibits an enormously harmful effect on the endothelium and drastically alters the dynamics of its cellular function. Hence, endothelial injury and dysfunction have been proposed as the initiating events of atherosclerosis. In the presence of cardiovascular risk factors including hyperlipidemia, hypercholesterolemia, smoking, diabetes, and hypertension, the likelihood of cardiovascular disease is highly augmented.

For quite some time, increased antioxidant intake has been investigated for its potential biochemical role in reducing the levels of ROS. Antioxidants are known to protect cells from the effects of free radical damage either by disturbing their mode of production or by attenuating their proliferation once they have formed. They accomplish the former by converting free radical reactants into stable species and the latter takes place via neutralizing the effects of free radical molecules. More precisely, these antioxidants often act by donating an unpaired electron to the unstable free radical, themselves now in the position of becoming a pro-oxidative species. Yet, the structure of antioxidants is usually such that their unpaired electron can be stabilized by adapting one of several possible resonance structures [192-194]. Hence, antioxidants appear to be a very viable preventative measure towards the onset of atherosclerosis and potentially subsequent cardiovascular disease. Long-term studies must be conducted to judge the dose-and time-dependency of the plethora of potential antioxidants. Many of these substances play several integral roles in the body and any beneficial outcomes may not be a direct result of a substance's anti-atherosclerotic properties, *per se*. Furthermore, atherosclerosis pathogenesis is outstandingly complicated and it is now known that the condition's progression is linked to a number of redox-sensitive events that extend beyond the oxidation of LDL [195]. A great deal more investigation will have to be undertaken in an attempt to determine which components of the oxidative stress state are critical for atherosclerosis and the precise mechanism by which antioxidants function.

### 4.5. Epigenetic regulation of eNOS

Until this point, nitric oxide production and inhibition have been discussed in the context of atherosclerotic plaque formation and their potential role in cardiovascular disease. Moreover, from an epigenetic perspective, the endothelium and its biochemical properties also present an incredibly fascinating model. In mammals, three isoforms of nitric oxide synthase (NOS), encoded by genes on distinct chromosomes: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS), are responsible for the production of nitric oxide [196-198]. The latter of these, eNOS, is known to be the dominant producer of NO and has been found to be constitutively expressed in the endothelium [199]. The eNOS gene, itself, contains 26 exons over the length of 21 kb of genomic DNA, maps to chromosome 7q35-36, and is present as a single copy in the haploid genome [196-198, 200]. Additionally, the gene's promoter has no proximal CpG island and a TATA box is also absent [201]. eNOS deficiency, in animals, has been linked to pulmonary hypertension, atypical vascular remodeling, and flawed angiogenesis [181, 202]. eNOS deficiency in humans has been observed in pulmonary hypertensive individuals and in the coating of advanced plaques [203]. Much attention has been given to discovering and documenting the regulation of eNOS *in vitro* as well as *in vivo*.

Transcriptional, posttranscriptional, and posttranslational pathways have been linked to the intriguing regulation of eNOS [199]. In addition to von Willebrand factor (vWF), vascular-endothelial cadherin (VE-cadherin), intercellular adhesion molecule-2 (ICAM-2), and the vascular endothelial growth factor receptors (VEGFR1 and VEGFR2), eNOS is one of many proteins whose expression is largely endothelial-cell specific [181]. This remarkable nuance has allowed for gene regulation study, from a predominantly epigenetic perspective.

The classic *cis/trans* mentality would be the simplest way to account for the endothelial-cell specificity that is observed in eNOS and the other abovementioned proteins. By this way of thinking, the *cis*-acting elements would bind the 5` regulatory regions of target genes in near proximity. *Trans*-acting factors would be recruited, but they themselves, would have to be cell-restricted in expression. This arrangement would describe gene expression regulated by a master transcription factor. Several well documented instances of master regulation, in mammalian biology, include NeuroD in neurons [204], smooth muscle cell myocardin [205], peroxisome proliferator-actived receptor-γ in adipocytes [206], with the most profound example being MyoD in skeletal muscle cells [207]. In spite of all of these examples, a master regulator in endothelial cells has yet to be discovered [181]. There are some transcription factors, such as Hey2, Vezf1, HoxA9 [181], and KLF2 [208] which are preferentially expressed in the vascular endothelium, but can also be found in other locales. Much research is dedicated to establishing the prominence of each of these in the vascular endothelium, especially KLF2 (kruppel-like factor 2). *Cis*-DNA binding elements in the 5`-regulatory regions have been found in a number of the endothelial-cell restricted genes, and the current train of thought tends towards the cooperative activity of a unique combination of transcription factors present in endothelial cells and not in any other cell type [181].

### 4.6. Role of DNA methylation & eNOS expression

A differentially methylated region (DMR) that had been detected in the proximal promoter of eNOS in expressing cell types has been observed to be unmethylated or lightly methylated whereas that same DMR in nonexpressing cell types was heavily methylated [209]. Combination of chromatin immunoprecipitation (ChIP) and quantitative real-time PCR revealed the preferential attraction of transcription factors Sp1, Sp3, and Ets1 to the eNOS proximal promoter of endothelial cells, even though they were also present in the tested nonexpressing cell type: vascular smooth muscle cells (VSMC) [209]. Not only did RNA polymerase II preferentially bind to the proximal promoter of eNOS in endothelial cells, but the transcriptionally repressive methyl-CpG-binding domain protein, MeCP2, was attracted to the promoter of VSMCs [210]. Upon treatment with the DNMT inhibitor, 5-azacytidine, those heavily methylated CpG sites were found to be unmethylated, while expression of the eNOS mRNA was seen to increase [209]. Hence, human eNOS is the first identified constitutively expressed vascular endothelium gene whose specificity in expression, is at least partially dictated by DNA methylation [209].

### 4.7. A histone code for the endothelium

Despite the prominence of DNA methylation pathways in these intricate biochemical sequences, other chromatin based mechanisms, especially histone posttranslational modifications, have been studied in the context of eNOS. Transcriptionally activating marks such as the acetylation of H3 and H4 as well as the di-and tri-methylation of H3K4 have been experimentally detected in nucleosomes of the eNOS proximal promoter in expressing, but not nonexpressing human cell types [211]. As would be predicted, histone deacetylases (HDAC1 but not HDAC 2 or 3) were found at the promoter region of nonendothelial cell types [211]. We used ChIP analysis which recognized, at the eNOS promoter in endothelial cells, the discernible enrichment of acetylated H3K9 and H4K12. The above observations support the existence of a histone code unique to the endothelium, whose precise posttranslational modifications are, to a degree, responsible for gene expression regulation in the endothelium [209, 211].

In summary, current studies are attempting to decipher the relative importance of both DNA methylation and histone posttranslational modifications in gene expression regulation in the vascular endothelium. The ways in which these patterns are initially laid down in development are likely complex and understanding them is still well into the future. It has been speculated that disturbances of these epigenetic pathways may have implications for human health and disease. As we have seen, decreased eNOS expression, and hence, reduced NO production, can have profound consequences for conditions such as atherosclerosis.

### 4.8. LncRNA and the cardiovascular system

With the traditional four base static genetic code failing to account for the missing heritability of complex genetic disease phenotypes, the dynamic epigenetic code is becoming widely accepted as an important determinant of cardiovascular pathologies [212]. Epigenetics provides a heritable link between our environment and diseases classically linked to genetics. It should come as no surprise, then, that if lncRNAs can act as epigenetic regulators they might have a crucial role to play in the development and homeostasis of the cardiovascular system (Figure 5).

Advances in genome sequencing have allowed for new genetic screening techniques that are more accurate than ever. Within the last decade, genome wide association studies (GWAS) have paved the way for understanding genetic variation in common complex diseases. While traditional family based and linkage analysis studies are effective in identifying rare disease causing mutations, they fail to uncover genetic variation amongst common diseases such as cardiovascular disease [213]. Advances in genomic sequencing have lead to the establishment of databases like the Human Genome Project and the Human Haplotype Map Project that have allowed GWAS to become a useful and accurate tool for correlating single nucleotide polymorphisms (SNPs) to disease phenotype when implemented correctly. Using microarray technologies, up to a million SNPs can be assessed.

Interest in cardiovascular epidemiology has led to a number of GWA studies examining coronary artery disease (CAD) [214]. These studies found an unexpected risk association at the 9p21 locus, a locus with few protein coding genes. This locus showed the strongest genetic

correlation to CAD, with ~20-25% of the Caucasian population homozygous for the risk haplotype corresponding to a 30-40% increase in CAD development [215]. Interestingly, however, the sequence of a recently described lncRNA, ANRIL (antisense non-coding RNA in the INK4 locus), was found to overlap with this genomic region [216]. These discoveries put the spotlight on ANRIL as a new potential regulator of cardiovascular integrity. As such, many recent studies have shed light on the functions of ANRIL. ANRIL is expressed in endothelial cells, vascular smooth muscle cells, and leukocytes, all of which are involved in the pathogenesis of atherosclerosis [217]. One of the key findings from studies with ANRIL was its function as an epigenetic regulator of the *INK4a/ARF/INK4b* locus. This locus encodes three proteins, p15, p14ARF, and p16, all with important implications as cell cycle regulators, which together slow cell proliferation. Initiation and maintenance of *INK4a/ARF/INK4b* gene repression is mediated by PRC2 and PRC1, respectively. As demonstrated by *Xist* and HOTAIR, PRC complexes seem to have a common relation to lncRNAs. ANRIL is no exception, and interacts with the SUZ12 subunit of PRC2 and the chromobox 7 (CBX7) subunit of PRC1, recruiting them in *cis* to the INK4a/ARF/INK4b locus. Indeed, knockdowns of ANRIL show a decrease in CBX7 and a subsequent increase in *INK4a/ARF/INK4b* gene expression. Although the exact mechanism of ANRIL's association to cardiovascular diseases has yet to be elucidated, the preliminary correlation has been made and further work may yet confirm ANRIL as the important regulatory molecule it is hypothesized to be.



**Figure 5.** ANRIL is expressed in tissues associated with atherosclerosis. Expression of ANRIL in leukocytes, VSMCs, and endothelial cells acts in *cis* to repress the neighboring INK4a/ARF/INK4b locus harboring important cell cycle regulators. Silencing occurs via the recruitment of PRC1 and PRC2 complexes and subsequent increase in the repressive H3K27me3 histone modification.

More recently, new studies have identified a number of lncRNAs associated with the cardiovascular system. Specifically, two lncRNA have emerged as potential regulators of murine cardiogenesis. One group of researchers has identified a novel lncRNA, deemed Braveheart

(Bvht), which plays a role in cardiac development [218]. Bvht is an ~590 nucleotide mouse-specific transcript that has been shown to be an essential regulator of cardiac commitment in embryonic stem cells. Knockdown of Bvht in mouse ES cells, which were allowed to differentiate into cardiomyocytes, showed a substantial decrease in the percent of contractile cells compared to the control. Although the mechanism is unclear, evidence suggests that Bvht functions upstream of the MesP1 pathway, a known regulator of cardiac mesoderm development [219]. Notably, Bvht, in agreement with an emerging theme among lncRNAs, was also shown to interact with PRC complexes [218]. Bvht interacts with the SUZ12 component of the PRC2 complex. This provides some insight into its function as a possible epigenetic regulator of cardiac gene expression, although it is not known whether this interaction acts to keep PRC2 from repressing genes needed for cardiogenesis, or if it functions to recruit the repressive complex to genes that inhibit this process.

Shortly after the discovery of Bvht, another group reported an lncRNA in mice, named Fendrr, which was similarly involved in the development of the heart [220]. Fendrr is expressed in the lateral mesoderm of the developing embryo, where it is required for differentiation into lateral mesoderm derivatives, most notably the cardiac mesoderm and ventral body wall. Accordingly, Fendrr null mutant embryos are embryonic lethal and display distinct phenotypic changes in the heart, such as cardiac hypoplasia and impaired function. Once again, epigenetic regulation by an lncRNA is the likely culprit for these outcomes. Fendrr null mutants show an increase in the activating H3K4me3 mark, laid down by the TrxG/MLL complex, at the promoters of the cardiac development regulators GATA6 and Nkx2-5. Co-immunoprecipitation assays also show an interaction between Fendrr and TrxG/MLL. Additionally, co-immunoprecipitation assays also show an interaction of Fendrr with TrxG/MLL and PRC2. Fendrr interacts with the PRC2 complex in both *cis* and *trans* to regulate transcription factors in the lateral and cardiac mesoderm. Fendrr is able to bind to a region near the neighbouring Foxf1 gene, where it is believed to anchor and guide PRC2 to the promoter region and increase H3K27me3.

The lncRNAs mentioned are likely only scratching the surface of important regulators of cardiovascular function. In fact, one recent study using high-throughput sequencing techniques to study VSMC in rats has identified 24 novel lncRNA differentially expressed in response to AngII [221]. Similarly, another study has shown, using high throughput RNA-seq techniques, that 135 non-coding genes show differential expression in failing murine hearts [222]. Together, these studies illustrate the complexity of the cardiovascular transcriptome. With thousands of putative lncRNAs, more studies will no doubt uncover similar associations to the cardiovascular system. Further insight into the function of these lncRNAs is crucial to realizing their contribution to epigenetics, and is a probable direction of many future studies.

### 4.9. Epigenetic inheritance

A vital component of the definition of epigenetics and one which has briefly been mentioned in this chapter is that of the heritability of epigenetic patterns. These patterns carry great significance for the determination and preservation of defined and consistent gene expression programs that underlie cell fate decisions during and beyond early development. Despite

flexibility of these patterns in totipotent and pluripotent stages, this plasticity wanes as development continues. The inheritance of such patterns is, therefore, of the utmost importance. The following section will explore the transmission of such information during the replication stages that take place in mitosis and meiosis, specifically analyzing DNA methylation and histone modification patterns within the context of these two processes.

DNA methylation is a significant epigenetic process that nicely fulfills the criterion for heritability. It has been proposed that DNA methylation may in fact act as a source of epigenetic memory, via the mitotic pathway. Previously, we offered a widely accepted and elegant sequence of events to describe the generational inheritance of DNA methylation patterns. *De novo* methyltransferases initially place methylation marks on DNA and, following replication, the maintenance DNMT marks the nascent strand with the same patterns exhibited by the original parent strand. Quite simply, DNA methylation absence demarcates active promoter regions, namely CpG islands, such that the promoters in which they are found remain potentially transcriptionally active throughout development and maturity. Conversely, segments of the genome that lack promoter activity become methylated and carry the flags of repression throughout the life of the organism. Our understanding of methylation pattern inheritance through mitosis is becoming relatively well elucidated, while more studies must be dedicated to comprehending the ways in which these patterns are initially laid down.

The semi-conservative model of inheritance that applies to both DNA replication and the transmission of DNA methylation patterns, had been speculated [223], and is now seldom conceived to be the main mode of transmission of histone modifications. Although compelling, this model relies on inherent symmetry within mono-nucleosomes as well as the semi-conservative separation of H3-H4 tetramers [224] (which, together with H2A and H2B dimers, make up the nucleosome core). Although two copies of each of the core histones are present within the nucleosome, it is unknown, yet highly doubted, that histone modifications exist in a symmetric manner [224]. Given the observation that the vast majority of H3-H4 tetramers actually segregate in a conservative manner [225-228], the more likely candidates to act as templates for new patterns would actually be adjacent, pre-existing nucleosomes on the same strand [224]. A possible mechanism for this may be envisioned whereby a neighbouring nucleosome that will be used as a template, is marked by a chromatin binding protein or reader protein [229] which would recruit a writer protein. Such a system may act in repetitive sequences where a number of nucleosomes all require the same replication. A self-cycling process has been proposed for up keeping repressive H3K27me3 marks, whereby polycomb repressive complex 2 (PRC2) binds to its own methylation site [230].

Based on these observations, the literal notion of copying a code during the S phase of the cell cycle does not seem to be applicable to the intricate system of histone modifications. In the next section, we mention that DNA methylation patterns likely influence the propagation of histone modifications. It may be speculated that the semi-conservative model applies well to DNA methylation pattern transmission, and the flags installed on the newly synthesized strand then act as markers for prompting the appropriate histone modifications.

Histone variant inheritance outside of S phase has suggested that histone modification inheritance can be replication-independent, unlike the events described above that would

predominate at the replication fork. Histone variants are altered versions of one of the four core histone proteins. For example, H3.3 has been shown to be associated with transcriptionally active segments and is found abundantly in active histone marks [231-233]. H3.3 nucleosomes are known to be more dynamic and susceptible to displacement during transcription [234]. Consequently, the density of H3.3 nucleosomes is reduced during transcription. The replication-independent re-incorporation of H3.3 appears to be mediated by chaperone proteins, such as HIRA (Hir-related protein A) following the completion of transcription [235, 236]. Hence, this particular epigenetic modification can be maintained, despite dilution by replication.

### 4.10. Histone code dispute

Occasionally, the "histone code" is discussed as an entity whose existence is well established, while, at other times, it proves to be a highly debated topic. In the following, we will briefly touch upon these disputable characteristics and why a consensus has yet to be reached in this matter. Numerous tables have been compiled in an attempt to categorize the diverse range of possible histone modifications and the assortment of amino acid residues that are subject to these alterations. In contrast to the genetic code, the universality and predictability of the potential histone code seem to be much less clear-cut. In stark contrast to the genetic code, the consistency of histone patterns seems to vary dramatically from lower to higher eukaryotes [237]. Evidence has accumulated which argues against the notion of a simple binary relationship between modification and effect.

Turner thoroughly reviewed the concept of a histone code, in light of the extensive possibilities that result from combinations of modification and amino acid, from the perspective of semiotics: the study of signs and their use or meaning [237]. The genetic code is highlighted as the quintessential semiotic code in the way that following the central dogma of molecular biology (DNA→RNA→protein) requires the utilization of symbols, their meaning, and a code to make known their meaning. Even though the symbols of an epigenetic code would likely be combinations of histone modifications with DNA methylation marks, the number of these is far from being known. Such arrangements would increase in quantity with increasing number of cell types and would have to be pinpointed at different moments in differentiation. At this point, we can only speculate as to the number of different outcomes based on the indefinite capacity for combination. Thus, it can be seen that, in order to accurately describe the transmission of histone modifications as a "code," a much more comprehensive synthesis of the variable arrangements must be attained.

### 4.11. Relationships between epigenetic pathways

Several attempts have been made at identifying the relationships between the discussed epigenetic pathways. DNA methylation and histone posttranslational modifications have been implicated in a wide variety of instances, many of which have been discussed in this chapter. Biochemical and genetic evidence have tended towards a bidirectional relationship between the two systems: histone methylation has been seen to guide DNA methylation and a DNA methylation template likely influences the reversible placement of histone modifications [238].

In the following, both of these options, in addition to the joint roles they play in repression, will be discussed.

We can now appreciate the dynamic nature of methylation patterns during early development. At approximately the implantation stage, a wave of *de novo* methylation inputs the methylation patterns that will be transferred to somatic cells in subsequent generations. At the same time, there is a mechanism, speculated to be the combinatorial binding of *cis*-acting elements and active demethylation, which serves to protect CpG islands from indiscriminate *de novo* methylation (40, 239-241). Interestingly, there is support for the notion that it is the presence of H3K4 mono-, di-, or tri-methylation that appears to protect CpG islands before the round of *de novo* DNA methylation begins (63, 242). Recent studies suggest that H3K4 methylation protects DNA from *de novo* methylation [243, 244]. RNA polymerase II is known to be bound primarily to CpG islands in the early embryo and is responsible for recruiting H3K4 methyltransferases (Table 1) (63, 243-246). Therefore, it is these regions that remain unmethylated as a result of early histone modifications.

Another significant event of early development occurs at the time of gastrulation when targeted repression and *de novo* methylation of pluripotency preserving genes such as *Oct3/4*, takes place [247]. A sequential process ensues: binding of repressor molecules with the *Oct3/4* promoter turns off transcription [248-250] and a complex containing the histone methyltransferase G9a as well as histone deacetylases are recruited. Deacetylation, one of the histone modifications associated with transcriptional repression, is the next step, resetting the lysine residues so that G9a is able to catalyze H3K9 methylation [251]. From here, the successive binding of heterochromatin protein 1 (HP1) facilitates the formation of heterochromatin [251]. Finally, G9a binding also recruits DNMT3A and 3B [252], meaning that the final stages of silencing are completed. Gastrulation is the time at which the embryo begins to separate into germ layers, losing the ability to maintain pluripotency. Accordingly, it is histone modifications, working in conjunction with DNA methylation pathways that direct the repression of the expression of pluripotency-associated genes.

In the above two examples, HP1 was discussed in the context of deacetylation, whereas H3K4 methylation was said to protect CpG islands from *de novo* DNA methylation in early development. There are other instances, however, where H3K4me acts as a binding site for HP1 [253, 254]. A major component of heterochromatin, HP1, is well known to contribute to the establishment and maintenance of transcriptionally silent heterochromatin [255].

In addition to these instances of histone modifications guiding DNA methylation patterns, there is evidence to suggest that, through cell division, DNA methylation is important for maintaining many histone modifications [251]. As discussed previously, DNA methylation patterns are faithfully transmitted to the next generation by means of the maintenance methyltransferase DNMT1 and prior UHRF1and PCNA DNA binding. However, despite the importance of chromatin structure and composition in initiating transcriptional patterns, these same structures are liable to disruption as the replication fork and associated complexes make their way along the DNA during replication [251]. It has been inferred that DNA methylation patterns may act as an important indicator for the reconstruction of epigenetic patterns. That

is, the more or less accurate transmission is likely necessary for the reproduction of chromatin conformation after replication has occurred.

Several studies have found that regions rich in unmethylated DNA are reformed in a rather open conformation, while those regions with more methylated DNA tend to be restructured in a sealed configuration [256, 257]. Acetylated (activating) histones are the primary component of those unmethylated, open regions. Conversely, it has also been shown that the nucleosomes of the compact, closed chromatin contain histones which are primarily non-acetylated [258, 259]. Also worth noting is the fact that methyl-CpG binding domain proteins such as MeCP2 and MBD2 also demonstrate the ability to attract histone deacetylases to methylated DNA regions [260, 261]. There is evidence that, in plants, DNA methylation may inhibit H3K4 methylation, a mark of activation, while perhaps also directing H3K9 dimethy-lation, a repressive indicator (259, 262, 263). Thus, even though the mechanism of action may still be relatively unknown for a number of these hypotheses, evidence does suggest the potential of a DNA methylation template guiding the placement of histone modifications.

Earlier in this chapter, upon describing the structure of nucleosomes, we mentioned the fact that ATP-dependent chromatin remodeling complexes often execute an action of nucleosome sliding. We revisit this topic here, in light of our exploration of the relationships amongst epigenetic pathways. The regulation of gene expression has also been found to be affected by these chromatin remodelers, namely the SNF2 family. Containing helical domains but executing no helicase activity, these proteins disturb the histone/DNA contacts and are believed to function in both transcriptional activation and repression, depending on the context [238]. Briefly, we will highlight a few key avenues of research. Jeddeloh *et al.* were the first to link DNA methylation with these SNF2 helicases [264]. In *A. thaliana*, mutation in a protein called DDM1 (decreased in DNA methylation) resulted in 70% diminishment in global DNA methylation levels [264]. The mammalian lymphoid specific helicase (Lsh) has been found to be the most closely related SNF2 member and has been linked to cell proliferation [238, 265]. Murine knockout experiments have demonstrated normal development until birth, but death occurs soon after because of renal lesions, as well as defects in lymphoid development and proliferation [238, 266].

Based on the above examples, there certainly seems to be some sort of connectivity between the epigenetic pathways. Crosstalk is clearly happening between histone posttranslational modifications and DNA methylation patterns, despite the fact that they are often studied independently. Future research would certainly focus on deciphering both the direct and indirect ways in which these processes act in tandem with one another.

# 5. Case study II: Dutch winter famine

It is a rare and tragic instance when a serious famine strikes an urban and industrialized setting, but exactly this happened in the winter of 1944-45 in West Netherlands. Excellent documentation of the event and the people most affected by it has allowed for the study of nutritional deprivation, in the form of famine, on human reproduction. Under German occupation, the

Western Netherlands suffered an unusually harsh winter, the effects of which were exacerbated by fuel shortages. Homes were not heated, grass and tulip bulbs were consumed, and every scrap of furniture was burned in a desperate effort to stay alive [267]. Food rationing has become an inevitably direct consequence of wartime events, and the Dutch Winter Famine was no exception to this phenomenon. A 1,800 calorie limit had been upheld for four years before mid-1944 when it was reduced to 1,600. A stark decline placed the limit at 400 calories in April of 1945 [267]. Although children as well as expectant and nursing mothers did receive slightly greater quantities, essentially every person suffered from severe hunger [268].

Case studies dedicated to investigating the impact of malnourished mothers on their offspring came about as a result of the initial Dutch Famine Birth Cohort Study. There are 2414 singletons born between November of 1943 and February of 1947 in Amsterdam for whom detailed birth records were collected and who, at the ages of 50 to 58, were surveyed as to their physical and mental health [268]. In general, low birth weight has been correlated with a number of conditions later in life: hypertension, insulin resistance, and obesity [268-271]. A decline in birth weight of up to 300g was seen among those exposed to maternal malnutrition in the third trimester [272]. The results of the Cohort study clearly demonstrated that exposure to famine at any point of gestation was associated with glucose intolerance [273]. Interestingly, the first trimester proved to be the most decisive stage of gestation at which maternal malnutrition impacts offspring health. Increased rates of coronary artery disease, atherogenic lipid accumulation, disturbed blood coagulation, type II diabetes, and cardiovascular disease were exhibited by those exposed to famine in early gestation. This Cohort Study clearly demonstrated that, not only is maternal famine exposure during gestation associated with chronic disease in offspring later life, but that effects varied based on the timing in gestation of famine exposure.

How can the solitary existence of the static DNA code account for such remarkable differences witnessed over the course of a single generation? Changes outside of the genome are needed to explain this trans-generational variation. To address this issue in more detail, Heijmans *et al*. focused on insulin-like growth factor 2 (IGF2), a maternally imprinted gene and a crucial factor in human growth and development, especially during gestation [274].To investigate whether maternal famine exposure was associated with differences in methylation of IGF2, 60 periconceptionally exposed people were compared with their same-sex sibling. Overall, exposure was found to be associated with an average reduction of 5.2% methylation in the DMR of IGF2. All CpG sites, except for one, were seen to be less methylated in those who had been exposed [274]. Statistically significant data showed periconceptional exposure, but not later exposure, was associated with this decrease. It is hypothesized that the deficiency of methyl donors such as the amino acid methionine, from reduced caloric intake, may account for the hypomethylation of IGF2 [274]. This study was the first to record persistent epigenetic changes in response to transient environmental conditions.

# 6. Concluding remarks

In this chapter, we have aimed to excite readers about the emerging field of epigenetics and the potential role it will play in future research initiatives. Without underscoring the importance of the genetic code, we have attempted to describe epigenetics in such a way that its significance is comparatively equivalent to that of genetics. The birth of the current molecular biological paradigm occurred relatively recently in the history of science, especially the history of scientific revolutions. Whether or not epigenetics is paving the way for a new paradigm in biology, is a debate that is best left to the philosophers of science. Yet, the relevancy of epigenetics cannot be understated as we embark on future investigations into human health and disease.

Known histone posttranslational modifications were explored first, and the repressive, activating, or joint consequences of a majority of alterations were delineated. Due to its duration of study, great emphasis was placed on DNA methylation, its consequences, mediators, and mechanisms of action. Then, we introduced the re-discovery of the promising 6th base pair: 5hmC. Although its role remains highly elusive, a great deal of research has been devoted to understanding the demethylation pathways in which this base is likely involved. Many of these options and their respective caveats were explored in the text. The observations that have been made about TET enzyme, DNA methylation, and DNA hydroxymethylation levels in zygotic development and PGC formation were also elucidated in this chapter and concisely summarized in Figure 3. Long non coding RNAs were discussed in their broad context as well as the role they play in the cardiovascular system.

Connections across the entire scope of the chapter were highlighted in our exploration of vitamin C. Its fascinating role in the human body cannot be understated. In scurvy, this vitamin's deficiency results in devastating physiological and psychological outcomes. Acting as both a co-factor for enzymatic reactions and as an antioxidant, the biochemical activity of ascorbate is also relevant in the context of cell culture and demethylation. Discovering the connections between P4H and TET enzyme structure has allowed the multi-faceted role of vitamin C in the epigenome, to also be elucidated. The pathogenesis of atherosclerosis was mechanized in such a way that the potential role of increased antioxidant intake was highlighted. Epigenetic regulation in the endothelium proves to be dynamic and highly changeable in the case of cardiovascular disease. eNOS gene regulation was thoroughly investigated as a representative case of highly endothelial-cell specific expression. Epigenetic inheritance at the replication fork was addressed in a DNA methylation and histone modification context. Crosstalk between these two pathways was discussed in the context of both DNA methylation patterns impacting those of histone modifications and vice versa. Finally, the Dutch Winter Famine was our second case study, this time further evaluating the role of transgenerational epigenetic inheritance in the context of severe maternal nutritional deprivation during pregnancy.

## List of non-standard Abbreviations and Acronyms

| | |
|---|---|
| **5caC** | 5-carboxylcytosine |
| **5hmC** | 5-hydroxymethylcytosine |
| **5fC** | 5-formylcytosine |
| **5mC** | 5-methylcytosine |
| **ATP** | adenosine triphosphate |
| **AID** | activation-induced cytidine deaminase |
| **APOBEC** | apolipoprotein B mRNA editing enzymes, catalytic polypeptide |
| **BER** | base excision repair |
| **ChIP** | chromatin immunoprecipitation |
| **CD domain** | Cys-rich and double stranded-helix DSBH region |
| **CpG** | cytosine - phosphate - guanine |
| **CGIs** | CpG islands |
| **DPPA3** | developmental pluripotency-associated 3 protein |
| **DNMTs** | DNA methyltransferases |
| **DMR** | differentially methylated region |
| **ES cell** | embryonic stem cell |
| **EC** | endothelial cell |
| **eNOS** | endothelial nitric oxide synthase |
| **EDRF** | endothelium-derived relaxing factor |
| **ES cell** | embryonic stem cell |
| **GWAS** | genome-wide association studies |
| **HATs** | histone acetyltransferases |
| **HDACs** | histone deacetylases |
| **HDMTs** | histone demethylases |
| **HOXC** | homeobox X |
| **IGF2** | insulin-like growth factor |
| **ICAM-2** | intercellular cell adhesion molecule-2 |
| **IAPs** | intracisternal A particles |
| **lnc-RNA** | long non-coding RNA |
| **MBDs** | methyl CpG binding domain proteins |
| **miRNA** | micro RNA |
| **MEFs** | mouse embryonic fibroblasts |
| **NO** | nitric oxide |
| **PRC2** | polycomb repressive complex 2 |
| **PGCs** | primordial germ cells |

| PCNA | proliferating cell nuclear antigen |
|---|---|
| P4H | prolyl 4-hydroxylase |
| ROS | reactive oxygen species |
| SAM | S-adenosylmethionine |
| SMUG1 | selective monofunctional uracil-DNA glycosylase 1 |
| SNP | single nucleotide polymorphism |
| SUMO | small ubiquitin-like modifier |
| TET enzymes | ten-eleven translocation enzymes |
| TDG | thymine DNA glycosylase |
| TSS | transcription start site |
| Ub | ubiquitin |
| UHRF1 | ubiquitin-like with PHD and ring finger domains 1 |
| VE-cadherin | vascular endothelial cadherin |
| VEGFR | vascular endothelial growth factor receptor |
| VSMC | vascular smooth muscle cell |
| vWF | von Willebrand factor |

## Acknowledgements

## Author details

Alexandra A. Majerski[1], Anthony C. Quinton[1] and Philip A. Marsden[1,2*]

*Address all correspondence to: p.marsden@utoronto.ca

1 The Keenan Research Centre and Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada

2 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada

The authors have no conflicts of interest to disclose.

# References

[1]   Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell. 2007 Feb 23;128(4):669-81.

[2]   Nightingale KP, O'Neill LP, Turner BM. Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr Opin Genet Dev. 2006 Apr;16(2):125-36.

[3]   Kornberg RD. Chromatin structure: a repeating unit of histones and DNA. Science. 1974 May 24;184(4139):868-71.

[4]   Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell. 5th ed. Masson S, Jeffcock E, Anderson M, Granum S, Goatly B, editors. New York, NY; Abingdon, UK: Garland Science, Taylor & Francis Group, LLC.; 2008.

[5]   Li G, Widom J. Nucleosomes facilitate their own invasion. Nat Struct Mol Biol. 2004 Aug;11(8):763-9.

[6]   Allfrey VG, Faulkner R, Mirsky AE. Acetylation and Methylation of Histones and Their Possible Role in the Regulation of Rna Synthesis. Proc Natl Acad Sci U S A. 1964 May;51:786-94.

[7]   Vaquero A, Loyola A, Reinberg D. The constantly changing face of chromatin. Sci Aging Knowledge Environ. 2003 Apr 9;2003(14):RE4.

[8]   Shogren-Knaak M, Ishii H, Sun JM, Pazin MJ, Davie JR, Peterson CL. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science. 2006 Feb 10;311(5762):844-7.

[9]   Vettese-Dadey M, Grant PA, Hebbes TR, Crane-Robinson C, Allis CD, Workman JL. Acetylation of histone H4 plays a primary role in enhancing transcription factor binding to nucleosomal DNA in vitro. EMBO J. 1996 May 15;15(10):2508-18.

[10]  Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM. Structure and ligand of a histone acetyltransferase bromodomain. Nature. 1999 Jun 3;399(6735): 491-6.

[11]  Owen DJ, Ornaghi P, Yang JC, Lowe N, Evans PR, Ballario P, et al. The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. EMBO J. 2000 Nov 15;19(22):6141-9.

[12]  Jenuwein T, Allis CD. Translating the histone code. Science. 2001 Aug 10;293(5532): 1074-80.

[13]  Lee DY, Teyssier C, Strahl BD, Stallcup MR. Role of protein methylation in regulation of transcription. Endocr Rev. 2005 Apr;26(2):147-70.

[14]  Zhang Y, Reinberg D. Transcription regulation by histone methylation: interplay be‐
      tween different covalent modifications of the core histone tails. Genes Dev. 2001 Sep
      15;15(18):2343-60.

[15]  Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol
      Cell Biol. 2005 Nov;6(11):838-49.

[16]  Langley E, Pearson M, Faretta M, Bauer UM, Frye RA, Minucci S, et al. Human SIR2
      deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J.
      2002 May 15;21(10):2383-96.

[17]  Wang H, Huang ZQ, Xia L, Feng Q, Erdjument-Bromage H, Strahl BD, et al. Methyla‐
      tion of histone H4 at arginine 3 facilitating transcriptional activation by nuclear hor‐
      mone receptor. Science. 2001 Aug 3;293(5531):853-7.

[18]  Fabbrizio E, El Messaoudi S, Polanowska J, Paul C, Cook JR, Lee JH, et al. Negative
      regulation of transcription by the type II arginine methyltransferase PRMT5. EMBO
      Rep. 2002 Jul;3(7):641-5.

[19]  Pal S, Yun R, Datta A, Lacomis L, Erdjument-Bromage H, Kumar J, et al. mSin3A/
      histone deacetylase 2-and PRMT5-containing Brg1 complex is involved in transcrip‐
      tional repression of the Myc target gene cad. Mol Cell Biol. 2003 Nov;23(21):7475-87.

[20]  Kouzarides T, Berger SL. In: Allis CD, Jenuwein T, Reinberg D, Caparros M-L, edi‐
      tors. Epigenetics. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press;
      2007. p. 191-206.

[21]  Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones RS, et al. Role of
      histone H2A ubiquitination in Polycomb silencing. Nature. 2004 Oct 14;431(7010):
      873-8.

[22]  Ehrlich M, Gama-Sosa MA, Huang LH, Midgett RM, Kuo KC, McCune RA, et al.
      Amount and distribution of 5-methylcytosine in human DNA from different types of
      tissues of cells. Nucleic Acids Res. 1982 Apr 24;10(8):2709-21.

[23]  Bird AP. CpG-rich islands and the function of DNA methylation. Nature. 1986 May
      15-21;321(6067):209-13.

[24]  Razin A, Riggs AD. DNA methylation and gene function. Science. 1980 Nov
      7;210(4470):604-10.

[25]  Wolf SF, Jolly DJ, Lunnen KD, Friedmann T, Migeon BR. Methylation of the hypo‐
      xanthine phosphoribosyltransferase locus on the human X chromosome: implications
      for X-chromosome inactivation. Proc Natl Acad Sci U S A. 1984 May;81(9):2806-10.

[26]  Li E, Bird A. In: Allis CD, Jenuwein T, Reinberg D, Caparros M-L, editors. Epigenet‐
      ics. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2007. p. 341-53.

[27] Watt F, Molloy PL. Cytosine methylation prevents binding to DNA of a HeLa cell transcription factor required for optimal expression of the adenovirus major late promoter. Genes Dev. 1988 Sep;2(9):1136-43.

[28] Hendrich B, Bird A. Identification and characterization of a family of mammalian methyl-CpG binding proteins. Mol Cell Biol. 1998 Nov;18(11):6538-47.

[29] Boyes J, Bird A. DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. Cell. 1991 Mar 22;64(6):1123-34.

[30] Hendrich B, Guy J, Ramsahoye B, Wilson VA, Bird A. Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse development. Genes Dev. 2001 Mar 15;15(6):710-23.

[31] Meehan RR, Lewis JD, McKay S, Kleiner EL, Bird AP. Identification of a mammalian protein that binds specifically to DNA containing methylated CpGs. Cell. 1989 Aug 11;58(3):499-507.

[32] Bird AP, Wolffe AP. Methylation-induced repression--belts, braces, and chromatin. Cell. 1999 Nov 24;99(5):451-4.

[33] Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet. 1998 Jul;19(3):219-20.

[34] Sharif J, Muto M, Takebayashi S, Suetake I, Iwamatsu A, Endo TA, et al. The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature. 2007 Dec 6;450(7171):908-12.

[35] Bostick M, Kim JK, Esteve PO, Clark A, Pradhan S, Jacobsen SE. UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science. 2007 Sep 21;317(5845): 1760-4.

[36] Chuang LS, Ian HI, Koh TW, Ng HH, Xu G, Li BF. Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science. 1997 Sep 26;277(5334): 1996-2000.

[37] Riggs AD. X inactivation, differentiation, and DNA methylation. Cytogenet Cell Genet. 1975;14(1):9-25.

[38] Holliday R, Pugh JE. DNA modification mechanisms and gene activity during development. Science. 1975 Jan 24;187(4173):226-32.

[39] Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell. 1992 Jun 12;69(6):915-26.

[40] Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999 Oct 29;99(3):247-57.

[41] Qiu C, Sawada K, Zhang X, Cheng X. The PWWP domain of mammalian DNA meth‐
yltransferase Dnmt3b defines a new family of DNA-binding folds. Nat Struct Biol.
2002 Mar;9(3):217-24.

[42] Lukasik SM, Cierpicki T, Borloz M, Grembecka J, Everett A, Bushweller JH. High res‐
olution structure of the HDGF PWWP domain: a potential DNA binding domain.
Protein Sci. 2006 Feb;15(2):314-23.

[43] Bird AP. DNA methylation and the frequency of CpG in animal DNA. Nucleic Acids
Res. 1980 Apr 11;8(7):1499-504.

[44] Coulondre C, Miller JH, Farabaugh PJ, Gilbert W. Molecular basis of base substitu‐
tion hotspots in Escherichia coli. Nature. 1978 Aug 24;274(5673):775-80.

[45] Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol.
1987 Jul 20;196(2):261-82.

[46] Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes
21 and 22. Proc Natl Acad Sci U S A. 2002 Mar 19;99(6):3740-5.

[47] Larsen F, Gundersen G, Lopez R, Prydz H. CpG islands as gene markers in the hu‐
man genome. Genomics. 1992 Aug;13(4):1095-107.

[48] Zhu J, He F, Hu S, Yu J. On the nature of human housekeeping genes. Trends Genet.
2008 Oct;24(10):481-4.

[49] Saxonov S, Berg P, Brutlag DL. A genome-wide analysis of CpG dinucleotides in the
human genome distinguishes two distinct classes of promoters. Proc Natl Acad Sci U
S A. 2006 Jan 31;103(5):1412-7.

[50] Ramirez-Carrozzi VR, Braas D, Bhatt DM, Cheng CS, Hong C, Doty KR, et al. A uni‐
fying model for the selective regulation of inducible transcription by CpG islands
and nucleosome remodeling. Cell. 2009 Jul 10;138(1):114-28.

[51] Tazi J, Bird A. Alternative chromatin structure at CpG islands. Cell. 1990 Mar
23;60(6):909-20.

[52] Schones DE, Cui K, Cuddapah S, Roh TY, Barski A, Wang Z, et al. Dynamic regula‐
tion of nucleosome positioning in the human genome. Cell. 2008 Mar 7;132(5):887-98.

[53] Choi JK. Contrasting chromatin organization of CpG islands and exons in the human
genome. Genome Biol.11(7):R70.

[54] Carninci P, Sandelin A, Lenhard B, Katayama S, Shimokawa K, Ponjavic J, et al. Ge‐
nome-wide analysis of mammalian promoter architecture and evolution. Nat Genet.
2006 Jun;38(6):626-35.

[55] Juven-Gershon T, Hsu JY, Theisen JW, Kadonaga JT. The RNA polymerase II core
promoter-the gateway to transcription. Curr Opin Cell Biol. 2008 Jun;20(3):253-9.

[56] Blackledge NP, Zhou JC, Tolstorukov MY, Farcas AM, Park PJ, Klose RJ. CpG islands recruit a histone H3 lysine 36 demethylase. Mol Cell. Apr 23;38(2):179-90.

[57] Strahl BD, Grant PA, Briggs SD, Sun ZW, Bone JR, Caldwell JA, et al. Set2 is a nucleosomal histone H3-selective methyltransferase that mediates transcriptional repression. Mol Cell Biol. 2002 Mar;22(5):1298-306.

[58] Youdell ML, Kizer KO, Kisseleva-Romanova E, Fuchs SM, Duro E, Strahl BD, et al. Roles for Ctk1 and Spt6 in regulating the different methylation states of histone H3 lysine 36. Mol Cell Biol. 2008 Aug;28(16):4915-26.

[59] Li B, Jackson J, Simon MD, Fleharty B, Gogol M, Seidel C, et al. Histone H3 lysine 36 dimethylation (H3K36me2) is sufficient to recruit the Rpd3s histone deacetylase complex and to repress spurious transcription. J Biol Chem. 2009 Mar 20;284(12):7970-6.

[60] Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008 Jul;40(7):897-903.

[61] Lee JH, Skalnik DG. CpG-binding protein (CXXC finger protein 1) is a component of the mammalian Set1 histone H3-Lys4 methyltransferase complex, the analogue of the yeast Set1/COMPASS complex. J Biol Chem. 2005 Dec 16;280(50):41725-31.

[62] Thomson JP, Skene PJ, Selfridge J, Clouaire T, Guy J, Webb S, et al. CpG islands influence chromatin structure via the CpG-binding protein Cfp1. Nature. Apr 15;464(7291):1082-6.

[63] Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. A chromatin landmark and transcription initiation at most promoters in human cells. Cell. 2007 Jul 13;130(1): 77-88.

[64] Mikkelsen TS, Ku M, Jaffe DB, Issac B, Lieberman E, Giannoukos G, et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature. 2007 Aug 2;448(7153):553-60.

[65] Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009 May 15;324(5929):930-5.

[66] Penn NW, Suwalski R, O'Riley C, Bojanowski K, Yura R. The presence of 5-hydroxymethylcytosine in animal deoxyribonucleic acid. Biochem J. 1972 Feb;126(4):781-90.

[67] Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science. 2009 May 15;324(5929):929-30.

[68] Munzel M, Globisch D, Bruckl T, Wagner M, Welzmiller V, Michalakis S, et al. Quantification of the sixth DNA base hydroxymethylcytosine in the brain. Angew Chem Int Ed Engl. Jul 19;49(31):5375-7.

[69] Szwagierczak A, Bultmann S, Schmidt CS, Spada F, Leonhardt H. Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res. Oct;38(19):e181.

[70] Ito S, Shen L, Dai Q, Wu SC, Collins LB, Swenberg JA, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science. Sep 2;333(6047):1300-3.

[71] Globisch D, Munzel M, Muller M, Michalakis S, Wagner M, Koch S, et al. Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One.5(12):e15367.

[72] Ficz G, Branco MR, Seisenberger S, Santos F, Krueger F, Hore TA, et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature. May 19;473(7347):398-402.

[73] Szulwach KE, Li X, Li Y, Song CX, Han JW, Kim S, et al. Integrating 5-hydroxymethylcytosine into the epigenomic landscape of human embryonic stem cells. PLoS Genet. Jun;7(6):e1002154.

[74] Branco MR, Ficz G, Reik W. Uncovering the role of 5-hydroxymethylcytosine in the epigenome. Nat Rev Genet. Jan;13(1):7-13.

[75] Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, Erdjument-Bromage H, et al. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet. 1999 Sep;23(1):58-61.

[76] Ng HH, Jeppesen P, Bird A. Active repression of methylated genes by the chromosomal protein MBD1. Mol Cell Biol. 2000 Feb;20(4):1394-406.

[77] Kass SU, Landsberger N, Wolffe AP. DNA methylation directs a time-dependent repression of transcription initiation. Curr Biol. 1997 Mar 1;7(3):157-65.

[78] Fujita N, Watanabe S, Ichimura T, Ohkuma Y, Chiba T, Saya H, et al. MCAF mediates MBD1-dependent transcriptional repression. Mol Cell Biol. 2003 Apr;23(8): 2834-43.

[79] Sarraf SA, Stancheva I. Methyl-CpG binding protein MBD1 couples histone H3 methylation at lysine 9 by SETDB1 to DNA replication and chromatin assembly. Mol Cell. 2004 Aug 27;15(4):595-605.

[80] Valinluck V, Tsai HH, Rogstad DK, Burdzy A, Bird A, Sowers LC. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucleic Acids Res. 2004;32(14): 4100-8.

[81] Jin SG, Kadam S, Pfeifer GP. Examination of the specificity of DNA methylation profiling techniques towards 5-methylcytosine and 5-hydroxymethylcytosine. Nucleic Acids Res. Jun;38(11):e125.

[82] Hashimoto H, Liu Y, Upadhyay AK, Chang Y, Howerton SB, Vertino PM, et al. Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation. Nucleic Acids Res. Jun;40(11):4841-9.

[83] Choy JS, Wei S, Lee JY, Tan S, Chu S, Lee TH. DNA methylation increases nucleosome compaction and rigidity. J Am Chem Soc. Feb 17;132(6):1782-3.

[84] Pastor WA, Aravind L, Rao A. TETonic shift: biological roles of TET proteins in DNA demethylation and transcription. Nat Rev Mol Cell Biol. Jun;14(6):341-56.

[85] He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. Sep 2;333(6047): 1303-7.

[86] Pfaffeneder T, Hackner B, Truss M, Munzel M, Muller M, Deiml CA, et al. The discovery of 5-formylcytosine in embryonic stem cell DNA. Angew Chem Int Ed Engl. Jul 25;50(31):7008-12.

[87] Iyer LM, Tahiliani M, Rao A, Aravind L. Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids. Cell Cycle. 2009 Jun 1;8(11):1698-710.

[88] Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature. Aug 26;466(7310):1129-33.

[89] Ko M, An J, Bandukwala HS, Chavez L, Aijo T, Pastor WA, et al. Modulation of TET2 expression and 5-methylcytosine oxidation by the CXXC domain protein IDAX. Nature. May 2;497(7447):122-6.

[90] Loenarz C, Schofield CJ. Physiological and biochemical aspects of hydroxylations and demethylations catalyzed by human 2-oxoglutarate oxygenases. Trends Biochem Sci. Jan;36(1):7-18.

[91] Upadhyay AK, Horton JR, Zhang X, Cheng X. Coordinated methyl-lysine erasure: structural and functional linkage of a Jumonji demethylase domain and a reader domain. Curr Opin Struct Biol. Dec;21(6):750-60.

[92] Tan L, Shi YG. Tet family proteins and 5-hydroxymethylcytosine in development and disease. Development. Jun;139(11):1895-902.

[93] Zhang H, Zhang X, Clark E, Mulcahey M, Huang S, Shi YG. TET1 is a DNA-binding protein that modulates DNA methylation and gene transcription via hydroxylation of 5-methylcytosine. Cell Res. Dec;20(12):1390-3.

[94] Xu Y, Wu F, Tan L, Kong L, Xiong L, Deng J, et al. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell. May 20;42(4):451-64.

[95] Bestor TH. Activation of mammalian DNA methyltransferase by cleavage of a Zn binding regulatory domain. EMBO J. 1992 Jul;11(7):2611-7.

[96] Khachane AN, Harrison PM. Mining mammalian transcript data for functional long non-coding RNAs. PLoS One.5(4):e10316.

[97] Webster AL, Yan MS, Marsden PA. Epigenetics and cardiovascular disease. Can J Cardiol. Jan;29(1):46-57.

[98] Saxena A, Carninci P. Long non-coding RNA modifies chromatin: epigenetic silencing by long non-coding RNAs. Bioessays. Nov;33(11):830-9.

[99] Brown CJ, Ballabio A, Rupert JL, Lafreniere RG, Grompe M, Tonlorenzi R, et al. A gene from the region of the human X inactivation centre is expressed exclusively from the inactive X chromosome. Nature. 1991 Jan 3;349(6304):38-44.

[100] Wutz A. Gene silencing in X-chromosome inactivation: advances in understanding facultative heterochromatin formation. Nat Rev Genet. Aug;12(8):542-53.

[101] Lee JT. Epigenetic regulation by long noncoding RNAs. Science. Dec 14;338(6113): 1435-9.

[102] Zhao J, Sun BK, Erwin JA, Song JJ, Lee JT. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome. Science. 2008 Oct 31;322(5902):750-6.

[103] Sado T, Wang Z, Sasaki H, Li E. Regulation of imprinted X-chromosome inactivation in mice by Tsix. Development. 2001 Apr;128(8):1275-86.

[104] Sun BK, Deaton AM, Lee JT. A transient heterochromatic state in Xist preempts X inactivation choice without RNA stabilization. Mol Cell. 2006 Mar 3;21(5):617-28.

[105] Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell. 2007 Jun 29;129(7):1311-23.

[106] Grier DG, Thompson A, Kwasniewska A, McGonigle GJ, Halliday HL, Lappin TR. The pathophysiology of HOX genes and their role in cancer. J Pathol. 2005 Jan;205(2): 154-71.

[107] Woo CJ, Kingston RE. HOTAIR lifts noncoding RNAs to new levels. Cell. 2007 Jun 29;129(7):1257-9.

[108] Lane N, Dean W, Erhardt S, Hajkova P, Surani A, Walter J, et al. Resistance of IAPs to methylation reprogramming may provide a mechanism for epigenetic inheritance in the mouse. Genesis. 2003 Feb;35(2):88-93.

[109] Morgan HD, Santos F, Green K, Dean W, Reik W. Epigenetic reprogramming in mammals. Hum Mol Genet. 2005 Apr 15;14 Spec No 1:R47-58.

[110] McLay DW, Clarke HJ. Remodelling the paternal chromatin at fertilization in mammals. Reproduction. 2003 May;125(5):625-33.

[111]　van der Heijden GW, Dieker JW, Derijck AA, Muller S, Berden JH, Braat DD, et al. Asymmetry in histone H3 variants and lysine methylation between paternal and maternal chromatin of the early mouse zygote. Mech Dev. 2005 Sep;122(9):1008-22.

[112]　Mayer W, Niveleau A, Walter J, Fundele R, Haaf T. Demethylation of the zygotic paternal genome. Nature. 2000 Feb 3;403(6769):501-2.

[113]　Oswald J, Engemann S, Lane N, Mayer W, Olek A, Fundele R, et al. Active demethylation of the paternal genome in the mouse zygote. Curr Biol. 2000 Apr 20;10(8): 475-8.

[114]　Santos F, Peters AH, Otte AP, Reik W, Dean W. Dynamic chromatin modifications characterise the first cell cycle in mouse embryos. Dev Biol. 2005 Apr 1;280(1):225-36.

[115]　Dean W, Santos F, Stojkovic M, Zakhartchenko V, Walter J, Wolf E, et al. Conservation of methylation reprogramming in mammalian development: aberrant reprogramming in cloned embryos. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13734-8.

[116]　Santos F, Hendrich B, Reik W, Dean W. Dynamic reprogramming of DNA methylation in the early mouse embryo. Dev Biol. 2002 Jan 1;241(1):172-82.

[117]　Wossidlo M, Nakamura T, Lepikhov K, Marques CJ, Zakhartchenko V, Boiani M, et al. 5-Hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming. Nat Commun.2:241.

[118]　Iqbal K, Jin SG, Pfeifer GP, Szabo PE. Reprogramming of the paternal genome upon fertilization involves genome-wide oxidation of 5-methylcytosine. Proc Natl Acad Sci U S A. Mar 1;108(9):3642-7.

[119]　Gu TP, Guo F, Yang H, Wu HP, Xu GF, Liu W, et al. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature. Sep 29;477(7366):606-10.

[120]　Borgel J, Guibert S, Li Y, Chiba H, Schubeler D, Sasaki H, et al. Targets and dynamics of promoter DNA methylation during early mouse development. Nat Genet. Dec; 42(12):1093-100.

[121]　Olek A, Walter J. The pre-implantation ontogeny of the H19 methylation imprint. Nat Genet. 1997 Nov;17(3):275-6.

[122]　Nakamura T, Liu YJ, Nakashima H, Umehara H, Inoue K, Matoba S, et al. PGC7 binds histone H3K9me2 to protect against conversion of 5mC to 5hmC in early embryos. Nature. Jun 21;486(7403):415-9.

[123]　Reik W. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature. 2007 May 24;447(7143):425-32.

[124]　Hackett JA, Sengupta R, Zylicz JJ, Murakami K, Lee C, Down TA, et al. Germline DNA demethylation dynamics and imprint erasure through 5-hydroxymethylcytosine. Science. Jan 25;339(6118):448-52.

[125] Carlson LL, Page AW, Bestor TH. Properties and localization of DNA methyltransferase in preimplantation mouse embryos: implications for genomic imprinting. Genes Dev. 1992 Dec;6(12B):2536-41.

[126] Hata K, Okano M, Lei H, Li E. Dnmt3L cooperates with the Dnmt3 family of de novo DNA methyltransferases to establish maternal imprints in mice. Development. 2002 Apr;129(8):1983-93.

[127] Kaneda M, Sado T, Hata K, Okano M, Tsujimoto N, Li E, et al. Role of de novo DNA methyltransferases in initiation of genomic imprinting and X-chromosome inactivation. Cold Spring Harb Symp Quant Biol. 2004;69:125-9.

[128] Pastor WA, Pape UJ, Huang Y, Henderson HR, Lister R, Ko M, et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature. May 19;473(7347):394-7.

[129] Wu H, Zhang Y. Tet1 and 5-hydroxymethylation: a genome-wide view in mouse embryonic stem cells. Cell Cycle. Aug 1;10(15):2428-36.

[130] Dawlaty MM, Ganz K, Powell BE, Hu YC, Markoulaki S, Cheng AW, et al. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell. Aug 5;9(2):166-75.

[131] Ko M, Bandukwala HS, An J, Lamperti ED, Thompson EC, Hastie R, et al. Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. Proc Natl Acad Sci U S A. Aug 30;108(35):14566-71.

[132] Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. Oct 27;118(17):4509-18.

[133] Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. Jul 12;20(1):11-24.

[134] Quivoron C, Couronne L, Della Valle V, Lopez CK, Plo I, Wagner-Ballon O, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell. Jul 12;20(1):25-38.

[135] Hajkova P, Erhardt S, Lane N, Haaf T, El-Maarri O, Reik W, et al. Epigenetic reprogramming in mouse primordial germ cells. Mech Dev. 2002 Sep;117(1-2):15-23.

[136] Hackett JA, Zylicz JJ, Surani MA. Parallel mechanisms of epigenetic reprogramming in the germline. Trends Genet. Apr;28(4):164-74.

[137] Hajkova P, Jeffries SJ, Lee C, Miller N, Jackson SP, Surani MA. Genome-wide reprogramming in the mouse germ line entails the base excision repair pathway. Science. Jul 2;329(5987):78-82.

[138]  Vincent JJ, Huang Y, Chen PY, Feng S, Calvopina JH, Nee K, et al. Stage-specific roles for tet1 and tet2 in DNA demethylation in primordial germ cells. Cell Stem Cell. Apr 4;12(4):470-8.

[139]  Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. Science. 2001 Aug 10;293(5532):1089-93.

[140]  Wu SC, Zhang Y. Active DNA demethylation: many roads lead to Rome. Nat Rev Mol Cell Biol. Sep;11(9):607-20.

[141]  Maiti A, Drohat AC. Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. J Biol Chem. Oct 14;286(41):35334-8.

[142]  Zhang L, Lu X, Lu J, Liang H, Dai Q, Xu GL, et al. Thymine DNA glycosylase specifi-cally recognizes 5-carboxylcytosine-modified DNA. Nat Chem Biol. Apr;8(4):328-30.

[143]  Morgan MT, Bennett MT, Drohat AC. Excision of 5-halogenated uracils by human thymine DNA glycosylase. Robust activity for DNA contexts other than CpG. J Biol Chem. 2007 Sep 21;282(38):27578-86.

[144]  Sibghat U, Gallinari P, Xu YZ, Goodman MF, Bloom LB, Jiricny J, et al. Base analog and neighboring base effects on substrate specificity of recombinant human G:T mis-match-specific thymine DNA-glycosylase. Biochemistry. 1996 Oct 1;35(39):12926-32.

[145]  Waters TR, Swann PF. Kinetics of the action of thymine DNA glycosylase. J Biol Chem. 1998 Aug 7;273(32):20007-14.

[146]  Abu M, Waters TR. The main role of human thymine-DNA glycosylase is removal of thymine produced by deamination of 5-methylcytosine and not removal of ethenocy-tosine. J Biol Chem. 2003 Mar 7;278(10):8739-44.

[147]  Maiti A, Morgan MT, Pozharski E, Drohat AC. Crystal structure of human thymine DNA glycosylase bound to DNA elucidates sequence-specific mismatch recognition. Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):8890-5.

[148]  Schiesser S, Hackner B, Pfaffeneder T, Muller M, Hagemeier C, Truss M, et al. Mech-anism and stem-cell activity of 5-carboxycytosine decarboxylation determined by iso-tope tracing. Angew Chem Int Ed Engl. Jun 25;51(26):6516-20.

[149]  Morgan HD, Dean W, Coker HA, Reik W, Petersen-Mahrt SK. Activation-induced cytidine deaminase deaminates 5-methylcytosine in DNA and is expressed in pluri-potent tissues: implications for epigenetic reprogramming. J Biol Chem. 2004 Dec 10;279(50):52353-60.

[150]  Zhu JK. Active DNA demethylation mediated by DNA glycosylases. Annu Rev Gen-et. 2009;43:143-66.

[151]  Chen ZX, Riggs AD. DNA methylation and demethylation in mammals. J Biol Chem. May 27;286(21):18347-53.

[152] Nabel CS, Jia H, Ye Y, Shen L, Goldschmidt HL, Stivers JT, et al. AID/APOBEC deaminases disfavor modified cytosines implicated in DNA demethylation. Nat Chem Biol. Sep;8(9):751-8.

[153] Guo JU, Su Y, Zhong C, Ming GL, Song H. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell. Apr 29;145(3): 423-34.

[154] Cortellino S, Xu J, Sannai M, Moore R, Caretti E, Cigliano A, et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell. Jul 8;146(1):67-79.

[155] Chen CC, Wang KY, Shen CK. The mammalian de novo DNA methyltransferases DNMT3A and DNMT3B are also DNA 5-hydroxymethylcytosine dehydroxymethylases. J Biol Chem. Sep 28;287(40):33116-21.

[156] Liutkeviciute Z, Lukinavicius G, Masevicius V, Daujotyte D, Klimasauskas S. Cytosine-5-methyltransferases add aldehydes to DNA. Nat Chem Biol. 2009 Jun;5(6): 400-2.

[157] Metivier R, Gallais R, Tiffoche C, Le Peron C, Jurkowska RZ, Carmouche RP, et al. Cyclical DNA methylation of a transcriptionally active promoter. Nature. 2008 Mar 6;452(7183):45-50.

[158] Kangaspeska S, Stride B, Metivier R, Polycarpou-Schwarz M, Ibberson D, Carmouche RP, et al. Transient cyclical methylation of promoter DNA. Nature. 2008 Mar 6;452(7183):112-5.

[159] Lamb J. Captain Cook and the Scourge of Scurvy. [BBC historical piece] 2011 [updated February 17 2011August 15 2013]; Available from: http://www.bbc.co.uk/history/british/empire_seapower/captaincook_scurvy_01.shtml#top.

[160] Davies MB, Austin J, Partridge DA. Vitamin C: Its Chemistry and Biochemistry. Cambridge: The Royal Society of Chemistry; 1991.

[161] Grollman AP, Lehninger AL. Enzymic synthesis of L-ascorbic acid in different animal species. Arch Biochem Biophys. 1957 Jul;69:458-67.

[162] Nishikimi M, Yagi K. Molecular basis for the deficiency in humans of gulonolactone oxidase, a key enzyme for ascorbic acid biosynthesis. Am J Clin Nutr. 1991 Dec;54(6 Suppl):1203S-8S.

[163] Shoulders MD, Raines RT. Collagen structure and stability. Annu Rev Biochem. 2009;78:929-58.

[164] Gorres KL, Raines RT. Prolyl 4-hydroxylase. Crit Rev Biochem Mol Biol. Apr;45(2): 106-24.

[165] Westbye MP, Feyzi E, Aas PA, Vagbo CB, Talstad VA, Kavli B, et al. Human AlkB homolog 1 is a mitochondrial protein that demethylates 3-methylcytosine in DNA and RNA. J Biol Chem. 2008 Sep 5;283(36):25046-56.

[166] Myllyla R, Kuutti-Savolainen ER, Kivirikko KI. The role of ascorbate in the prolyl hydroxylase reaction. Biochem Biophys Res Commun. 1978 Jul 28;83(2):441-8.

[167] Nietfeld JJ, Kemp A. The function of ascorbate with respect to prolyl 4-hydroxylase activity. Biochim Biophys Acta. 1981 Jan 15;657(1):159-67.

[168] de Jong L, Albracht SP, Kemp A. Prolyl 4-hydroxylase activity in relation to the oxidation state of enzyme-bound iron. The role of ascorbate in peptidyl proline hydroxylation. Biochim Biophys Acta. 1982 Jun 4;704(2):326-32.

[169] De Jong L, Kemp A. Stoicheiometry and kinetics of the prolyl 4-hydroxylase partial reaction. Biochim Biophys Acta. 1984 May 31;787(1):105-11.

[170] Peterkofsky B. Ascorbate requirement for hydroxylation and secretion of procollagen: relationship to inhibition of collagen synthesis in scurvy. Am J Clin Nutr. 1991 Dec;54(6 Suppl):1135S-40S.

[171] Padh H. Vitamin C: newer insights into its biochemical functions. Nutr Rev. 1991 Mar;49(3):65-70.

[172] Rebouche CJ. Ascorbic acid and carnitine biosynthesis. Am J Clin Nutr. 1991 Dec;54(6 Suppl):1147S-52S.

[173] Minor EA, Court BL, Young JI, Wang G. Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine. J Biol Chem. May 10;288(19):13669-74.

[174] Chung TL, Brena RM, Kolle G, Grimmond SM, Berman BP, Laird PW, et al. Vitamin C promotes widespread yet specific DNA demethylation of the epigenome in human embryonic stem cells. Stem Cells. Oct;28(10):1848-55.

[175] Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980 Nov 27;288(5789):373-6.

[176] Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9265-9.

[177] Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987 Jun 11-17;327(6122):524-6.

[178] Lefer AM. Nitric oxide: nature's naturally occurring leukocyte inhibitor. Circulation. 1997 Feb 4;95(3):553-4.

[179] Gauthier TW, Scalia R, Murohara T, Guo JP, Lefer AM. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995 Oct;15(10):1652-9.

[180] de Graaf JC, Banga JD, Moncada S, Palmer RM, de Groot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation. 1992 Jun;85(6):2284-90.

[181] Fish JE, Marsden PA. Endothelial nitric oxide synthase: insight into cell-specific gene regulation in the vascular endothelium. Cell Mol Life Sci. 2006 Jan;63(2):144-62.

[182] Gallo R, Fuster V. In: Tardif J-C, Bourassa MG, editors. Antioxidants and Cardiovascular Disease. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2000. p. 19-46.

[183] Stary HC. The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. Eur Heart J. 1990 Aug;11 Suppl E:3-19.

[184] Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W, Jr., Rosenfeld ME, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994 May;89(5):2462-78.

[185] Cathcart MK, Morel DW, Chisolm GM, 3rd. Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. J Leukoc Biol. 1985 Aug;38(2):341-50.

[186] Parthasarathy S, Printz DJ, Boyd D, Joy L, Steinberg D. Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor. Arteriosclerosis. 1986 Sep-Oct;6(5):505-10.

[187] Morel DW, DiCorleto PE, Chisolm GM. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis. 1984 Jul-Aug;4(4):357-64.

[188] Navab M, Hama SY, Nguyen TB, Fogelman AM. Monocyte adhesion and transmigration in atherosclerosis. Coron Artery Dis. 1994 Mar;5(3):198-204.

[189] Ross R. The pathogenesis of atherosclerosis--an update. N Engl J Med. 1986 Feb 20;314(8):488-500.

[190] Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993 Apr 29;362(6423):801-9.

[191] Guyton JR, Klemp KF. Development of the lipid-rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol. 1996 Jan;16(1):4-11.

[192] Mason RP, Walter MF, Trumbore MW, Olmstead EG, Jr., Mason PE. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol. 1999 Jan;31(1):275-81.

[193] Mason RP, Rhodes DG, Herbette LG. Reevaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J Med Chem. 1991 Mar;34(3):869-77.

[194] Mason RP, Campbell SF, Wang SD, Herbette LG. Comparison of location and binding for the positively charged 1,4-dihydropyridine calcium channel antagonist amlodipine with uncharged drugs of this class in cardiac membranes. Mol Pharmacol. 1989 Oct;36(4):634-40.

[195] John F. Keaney J. In: Tardif J-C, Bourassa MG, editors. Antioxidants and Cardiovascular Disease. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2000. p. 101-16.

[196] Marsden PA, Heng HH, Scherer SW, Stewart RJ, Hall AV, Shi XM, et al. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem. 1993 Aug 15;268(23):17478-88.

[197] Nadaud S, Bonnardeaux A, Lathrop M, Soubrier F. Gene structure, polymorphism and mapping of the human endothelial nitric oxide synthase gene. Biochem Biophys Res Commun. 1994 Feb 15;198(3):1027-33.

[198] Robinson LJ, Weremowicz S, Morton CC, Michel T. Isolation and chromosomal localization of the human endothelial nitric oxide synthase (NOS3) gene. Genomics. 1994 Jan 15;19(2):350-7.

[199] Tai SC, Robb GB, Marsden PA. Endothelial nitric oxide synthase: a new paradigm for gene regulation in the injured blood vessel. Arterioscler Thromb Vasc Biol. 2004 Mar; 24(3):405-12.

[200] Marsden PA, Schappert KT, Chen HS, Flowers M, Sundell CL, Wilcox JN, et al. Molecular cloning and characterization of human endothelial nitric oxide synthase. FEBS Lett. 1992 Aug 3;307(3):287-93.

[201] Matouk CC, Marsden PA. Epigenetic regulation of vascular endothelial gene expression. Circ Res. 2008 Apr 25;102(8):873-87.

[202] Liu VW, Huang PL. Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice. Cardiovasc Res. 2008 Jan;77(1):19-29.

[203] Wilcox JN, Subramanian RR, Sundell CL, Tracey WR, Pollock JS, Harrison DG, et al. Expression of multiple isoforms of nitric oxide synthase in normal and atherosclerotic vessels. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2479-88.

[204] Bertrand N, Castro DS, Guillemot F. Proneural genes and the specification of neural cell types. Nat Rev Neurosci. 2002 Jul;3(7):517-30.

[205] Wang Z, Wang DZ, Pipes GC, Olson EN. Myocardin is a master regulator of smooth muscle gene expression. Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):7129-34.

[206] Lehrke M, Lazar MA. The many faces of PPARgamma. Cell. 2005 Dec 16;123(6):993-9.

[207] Tapscott SJ. The circuitry of a master switch: Myod and the regulation of skeletal muscle gene transcription. Development. 2005 Jun;132(12):2685-95.

[208] Atkins GB, Jain MK. Role of Kruppel-like transcription factors in endothelial biology. Circ Res. 2007 Jun 22;100(12):1686-95.

[209] Chan Y, Fish JE, D'Abreo C, Lin S, Robb GB, Teichert AM, et al. The cell-specific expression of endothelial nitric-oxide synthase: a role for DNA methylation. J Biol Chem. 2004 Aug 13;279(33):35087-100.

[210] Teichert AM, Karantzoulis-Fegaras F, Wang Y, Mawji IA, Bei X, Gnanapandithen K, et al. Characterization of the murine endothelial nitric oxide synthase promoter. Biochim Biophys Acta. 1998 Dec 22;1443(3):352-7.

[211] Fish JE, Matouk CC, Rachlis A, Lin S, Tai SC, D'Abreo C, et al. The expression of endothelial nitric-oxide synthase is controlled by a cell-specific histone code. J Biol Chem. 2005 Jul 1;280(26):24824-38.

[212] Matouk CC, Turgeon PJ, Marsden PA. Epigenetics and stroke risk-beyond the static DNA code. Advances in Genomics and Genetics. 2012;2012:2:67-84.

[213] Bush WS, Moore JH. Chapter 11: Genome-wide association studies. PLoS Comput Biol.8(12):e1002822.

[214] Samani NJ, Erdmann J, Hall AS, Hengstenberg C, Mangino M, Mayer B, et al. Genomewide association analysis of coronary artery disease. N Engl J Med. 2007 Aug 2;357(5):443-53.

[215] McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007 Jun 8;316(5830):1488-91.

[216] Bown MJ, Braund PS, Thompson J, London NJ, Samani NJ, Sayers RD. Association between the coronary artery disease risk locus on chromosome 9p21.3 and abdominal aortic aneurysm. Circ Cardiovasc Genet. 2008 Oct;1(1):39-42.

[217] Broadbent HM, Peden JF, Lorkowski S, Goel A, Ongen H, Green F, et al. Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p. Hum Mol Genet. 2008 Mar 15;17(6):806-14.

[218] Klattenhoff CA, Scheuermann JC, Surface LE, Bradley RK, Fields PA, Steinhauser ML, et al. Braveheart, a long noncoding RNA required for cardiovascular lineage commitment. Cell. Jan 31;152(3):570-83.

[219] Lindsley RC, Gill JG, Murphy TL, Langer EM, Cai M, Mashayekhi M, et al. Mesp1 coordinately regulates cardiovascular fate restriction and epithelial-mesenchymal transition in differentiating ESCs. Cell Stem Cell. 2008 Jul 3;3(1):55-68.

[220] Grote P, Wittler L, Hendrix D, Koch F, Wahrisch S, Beisaw A, et al. The tissue-specific lncRNA Fendrr is an essential regulator of heart and body wall development in the mouse. Dev Cell. Jan 28;24(2):206-14.

[221] Leung A, Trac C, Jin W, Lanting L, Akbany A, Saetrom P, et al. Novel Long Non-Coding RNAs Are Regulated by Angiotensin II in Vascular Smooth Muscle Cells. Circ Res. May 22.

[222] Lee JH, Gao C, Peng G, Greer C, Ren S, Wang Y, et al. Analysis of transcriptome complexity through RNA sequencing in normal and failing murine hearts. Circ Res. Dec 9;109(12):1332-41.

[223] Annunziato AT. Split decision: what happens to nucleosomes during DNA replication? J Biol Chem. 2005 Apr 1;280(13):12065-8.

[224] Zhu B, Reinberg D. Epigenetic inheritance: uncontested? Cell Res. Mar;21(3):435-41.

[225] Leffak IM, Grainger R, Weintraub H. Conservative assembly and segregation of nucleosomal histones. Cell. 1977 Nov;12(3):837-45.

[226] Jackson V. In vivo studies on the dynamics of histone-DNA interaction: evidence for nucleosome dissolution during replication and transcription and a low level of dissolution independent of both. Biochemistry. 1990 Jan 23;29(3):719-31.

[227] Yamasu K, Senshu T. Conservative segregation of tetrameric units of H3 and H4 histones during nucleosome replication. J Biochem. 1990 Jan;107(1):15-20.

[228] Xu M, Long C, Chen X, Huang C, Chen S, Zhu B. Partitioning of histone H3-H4 tetramers during DNA replication-dependent chromatin assembly. Science. Apr 2;328(5974):94-8.

[229] Taverna SD, Li H, Ruthenburg AJ, Allis CD, Patel DJ. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat Struct Mol Biol. 2007 Nov;14(11):1025-40.

[230] Hansen KH, Bracken AP, Pasini D, Dietrich N, Gehani SS, Monrad A, et al. A model for transmission of the H3K27me3 epigenetic mark. Nat Cell Biol. 2008 Nov;10(11):1291-300.

[231] Loyola A, Bonaldi T, Roche D, Imhof A, Almouzni G. PTMs on H3 variants before chromatin assembly potentiate their final epigenetic state. Mol Cell. 2006 Oct 20;24(2):309-16.

[232] McKittrick E, Gafken PR, Ahmad K, Henikoff S. Histone H3.3 is enriched in covalent modifications associated with active chromatin. Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1525-30.

[233] Ahmad K, Henikoff S. The histone variant H3.3 marks active chromatin by replication-independent nucleosome assembly. Mol Cell. 2002 Jun;9(6):1191-200.

[234] Probst AV, Dunleavy E, Almouzni G. Epigenetic inheritance during the cell cycle. Nat Rev Mol Cell Biol. 2009 Mar;10(3):192-206.

[235] Tagami H, Ray-Gallet D, Almouzni G, Nakatani Y. Histone H3.1 and H3.3 complexes mediate nucleosome assembly pathways dependent or independent of DNA synthesis. Cell. 2004 Jan 9;116(1):51-61.

[236] Ray-Gallet D, Quivy JP, Scamps C, Martini EM, Lipinski M, Almouzni G. HIRA is critical for a nucleosome assembly pathway independent of DNA synthesis. Mol Cell. 2002 May;9(5):1091-100.

[237] Turner BM. Defining an epigenetic code. Nat Cell Biol. 2007 Jan;9(1):2-6.

[238] Geiman TM, Robertson KD. Chromatin remodeling, histone modifications, and DNA methylation-how does it all fit together? J Cell Biochem. 2002;87(2):117-25.

[239] Brandeis M, Frank D, Keshet I, Siegfried Z, Mendelsohn M, Nemes A, et al. Sp1 elements protect a CpG island from de novo methylation. Nature. 1994 Sep 29;371(6496):435-8.

[240] Siegfried Z, Eden S, Mendelsohn M, Feng X, Tsuberi BZ, Cedar H. DNA methylation represses transcription in vivo. Nat Genet. 1999 Jun;22(2):203-6.

[241] Macleod D, Charlton J, Mullins J, Bird AP. Sp1 sites in the mouse aprt gene promoter are required to prevent methylation of the CpG island. Genes Dev. 1994 Oct 1;8(19):2282-92.

[242] Ooi SK, Qiu C, Bernstein E, Li K, Jia D, Yang Z, et al. DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature. 2007 Aug 9;448(7154):714-7.

[243] Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature. 2008 Aug 7;454(7205):766-70.

[244] Weber M, Hellmann I, Stadler MB, Ramos L, Paabo S, Rebhan M, et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome. Nat Genet. 2007 Apr;39(4):457-66.

[245] Mohn F, Weber M, Rebhan M, Roloff TC, Richter J, Stadler MB, et al. Lineage-specific polycomb targets and de novo DNA methylation define restriction and potential of neuronal progenitors. Mol Cell. 2008 Jun 20;30(6):755-66.

[246] Okitsu CY, Hsieh CL. DNA methylation dictates histone H3K4 methylation. Mol Cell Biol. 2007 Apr;27(7):2746-57.

[247] Gidekel S, Bergman Y. A unique developmental pattern of Oct-3/4 DNA methylation is controlled by a cis-demodification element. J Biol Chem. 2002 Sep 13;277(37):34521-30.

[248] Fuhrmann G, Chung AC, Jackson KJ, Hummelke G, Baniahmad A, Sutter J, et al. Mouse germline restriction of Oct4 expression by germ cell nuclear factor. Dev Cell. 2001 Sep;1(3):377-87.

[249] Ben-Shushan E, Sharir H, Pikarsky E, Bergman Y. A dynamic balance between ARP-1/COUP-TFII, EAR-3/COUP-TFI, and retinoic acid receptor:retinoid X receptor heterodimers regulates Oct-3/4 expression in embryonal carcinoma cells. Mol Cell Biol. 1995 Feb;15(2):1034-48.

[250] Sylvester I, Scholer HR. Regulation of the Oct-4 gene by nuclear receptors. Nucleic Acids Res. 1994 Mar 25;22(6):901-11.

[251] Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009 May;10(5):295-304.

[252] Feldman N, Gerson A, Fang J, Li E, Zhang Y, Shinkai Y, et al. G9a-mediated irreversible epigenetic inactivation of Oct-3/4 during early embryogenesis. Nat Cell Biol. 2006 Feb;8(2):188-94.

[253] Bannister AJ, Zegerman P, Partridge JF, Miska EA, Thomas JO, Allshire RC, et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature. 2001 Mar 1;410(6824):120-4.

[254] Lachner M, O'Carroll D, Rea S, Mechtler K, Jenuwein T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature. 2001 Mar 1;410(6824):116-20.

[255] Bachman KE, Rountree MR, Baylin SB. Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterochromatin. J Biol Chem. 2001 Aug 24;276(34):32282-7.

[256] Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet. 2008 Jun;9(6):465-76.

[257] Weber M, Schubeler D. Genomic patterns of DNA methylation: targets and function of an epigenetic mark. Curr Opin Cell Biol. 2007 Jun;19(3):273-80.

[258] Eden S, Hashimshony T, Keshet I, Cedar H, Thorne AW. DNA methylation models histone acetylation. Nature. 1998 Aug 27;394(6696):842.

[259] Hashimshony T, Zhang J, Keshet I, Bustin M, Cedar H. The role of DNA methylation in setting up chromatin structure during development. Nat Genet. 2003 Jun;34(2): 187-92.

[260] Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 1998 May 28;393(6683):386-9.

[261] Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet. 1998 Jun;19(2):187-91.

[262] Lande-Diner L, Zhang J, Ben-Porath I, Amariglio N, Keshet I, Hecht M, et al. Role of DNA methylation in stable gene repression. J Biol Chem. 2007 Apr 20;282(16): 12194-200.

[263] Zilberman D, Coleman-Derr D, Ballinger T, Henikoff S. Histone H2A.Z and DNA methylation are mutually antagonistic chromatin marks. Nature. 2008 Nov 6;456(7218):125-9.

[264] Jeddeloh JA, Stokes TL, Richards EJ. Maintenance of genomic methylation requires a SWI2/SNF2-like protein. Nat Genet. 1999 May;22(1):94-7.

[265] Raabe EH, Abdurrahman L, Behbehani G, Arceci RJ. An SNF2 factor involved in mammalian development and cellular proliferation. Dev Dyn. 2001 May;221(1): 92-105.

[266] Geiman TM, Muegge K. Lsh, an SNF2/helicase family member, is required for prolif-eration of mature T lymphocytes. Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4772-7.

[267] Hart N. Famine, maternal nutrition and infant mortality: a re-examination of the Dutch hunger winter. Popul Stud (Camb). 1993 Mar;47(1):27-46.

[268] Roseboom T, de Rooij S, Painter R. The Dutch famine and its long-term consequences for adult health. Early Hum Dev. 2006 Aug;82(8):485-91.

[269] Newsome CA, Shiell AW, Fall CH, Phillips DI, Shier R, Law CM. Is birth weight re-lated to later glucose and insulin metabolism?--A systematic review. Diabet Med. 2003 May;20(5):339-48.

[270] Curhan GC, Chertow GM, Willett WC, Spiegelman D, Colditz GA, Manson JE, et al. Birth weight and adult hypertension and obesity in women. Circulation. 1996 Sep 15;94(6):1310-5.

[271] de Rooij SR, Painter RC, Roseboom TJ, Phillips DI, Osmond C, Barker DJ, et al. Glu-cose tolerance at age 58 and the decline of glucose tolerance in comparison with age 50 in people prenatally exposed to the Dutch famine. Diabetologia. 2006 Apr;49(4): 637-43.

[272] Lumey LH, Stein AD, Kahn HS, van der Pal-de Bruin KM, Blauw GJ, Zybert PA, et al. Cohort profile: the Dutch Hunger Winter families study. Int J Epidemiol. 2007 Dec;36(6):1196-204.

[273] Ravelli AC, van der Meulen JH, Michels RP, Osmond C, Barker DJ, Hales CN, et al. Glucose tolerance in adults after prenatal exposure to famine. Lancet. 1998 Jan 17;351(9097):173-7.

[274] Heijmans BT, Tobi EW, Stein AD, Putter H, Blauw GJ, Susser ES, et al. Persistent epi-genetic differences associated with prenatal exposure to famine in humans. Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17046-9.